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Dengue virus (DENV) is among the most important human 
arboviral pathogens. The virus infects about 50 million people 
worldwide leading to broad spectrum of outcome from a mild febrile 
illness to fatal haemorrhage and shock syndrome (Endy et al., 2010) 
and there are currently no clinically approved vaccines or antivirals for 
this disease. DENV has three structural and seven non-structural 
proteins (NS). NS5 has RNA-dependent RNA polymerase (RdRp) 
activity which plays a major role in viral replication and has also been 
associated with disease pathogenesis.  DENV RdRp domain has been 
identified by X-ray crystallography to bind several non-nucleoside 
inhibitors. Thus, this research study was to assess the drug-ability and 
relevance of the RdRp binding pocket of two non-nucleoside inhibitor 
compounds from Novartis Institute for Tropical Diseases (NITD) that 
binds to the catalytic domain of the enzyme.  
Experiments were done to investigate the importance of the 
inhibitor binding pocket for in vitro polymerase activity and as well for 
replication fitness in context of the DENV 2 TSV01 infectious virus. For 
these studies, individual amino acids lining this pocket that interacted 
with the inhibitors were mutated to alanine. Biochemical enzymatic 
assays were used to measure the ability of the RdRp proteins to carry 
out de novo initiation and elongation activities. Results obtained 
showed decreased enzymatic activities for full length (FL) NS5 F399A, 
K402A, F486A, N493A, Y607A, N610A and D664A proteins whilst 
G605A and W796A proteins displayed an increase in de novo initiation 
x 
 
activity but with no distinct change in elongation activity compared to 
the wild-type (WT) protein.  
The exception was Y607A which demonstrated significant 
increase in RdRp elongation activity whilst G605A also showed a slight 
decrease in activity. K402 residue showed to be required for both de 
novo initiation and elongation process whilst Y607 was determined to 
play an essential role in polymerase activity only during de novo 
initiation of viral RNA synthesis. Residues F486 and G605 generally 
demonstrated no effect in both de novo initiation and elongation steps 
of RNA replication suggesting that these residues are not crucial for 
RdRp enzyme activity.  
 Similarly, engineering of five mutated residues into genomic 
RNA of infectious clone for viral infection studies showed that residues 
F399, N493, N610 and D664 are critical for viral replication. These 
residues have also demonstrated a significant role in functioning both 
at the step of de novo initiation and elongation during the synthesis of 
RNA. W796A exhibited ~50% decrease in IFA positive cells and was 
able to recover less than 25% of virus titres as compared to WT which 
was in contrast to its remarkable performance during in vitro enzyme 
activity studies. This work contributes to understanding the biological 
function of residues lining the RdRp catalytic domain in DENV NS5. 
Gaining insight into specific active site residues is essential for the 
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1.1     Evolution of Dengue Virus 
               Dengue viruses (DENV) are the most important human 
arboviral pathogens. Transmission of the virus in tropical and 
subtropical regions of the world includes sylvatic or enzootic cycle 
between nonhuman primates and mosquito vectors such as Aedes 
furcifer, Aedes luteocephalus, Aedes taylori as well as an urban 
endemic or epidemic cycle principally between Aedes aegypti vector 
and humans (Cardosa et al., 2009). DENV evolutionary path differs in 
several aspects from its Flavivirus cousins, though it retains many of 
the same clinical characteristics as severe fever (Bennett, 2010).  
               Studies have shown that dengue virus like some other 
flaviviruses, was previously an enzootic indicating that its major 
transmission in humans were likely to have evolved from non-human 
primates about 100 to 1500 years ago to a sustained human 
transmission (Wang et al. 2000). Thus DENV infection in humans might 
have been incidental but have since established themselves as four 
distinct serotypes (DENV 1, DENV 2, DENV 3 and DENV 4) during the 
last century resulting in periodic epidemics and severe disease (Wang 
et al. 2000; Cardosa et al., 2009). The contemporary genetic diversity 
seen in all four dengue serotypes could as well be attributed to the 
continuous increase in population density and mass transport of both 
virus and its mosquito vector. 




1.2 Divergence from Non-infectious to an Infectious Pathogen 
 Within each serotype, DENV are organized by genotypes, 
subtypes, clades, variants, groups and finally strains (Figure 1.1). A 
phylogenetic study of different dengue viruses has led to the 
association between specific genotypes (within serotypes) and the 
presentation of more or less severe disease. It has been suggested 
that the immune status and possibly the genetic background of the 
human host are also determinants of virulence or disease presentation 
(Rico-Hesse, 2003). Whereby, specific viral structures may contribute 
to increased replication in host target cells and to an increased 
transmission by the mosquito vector.  
 The comparison of nucleotide sequences from the envelope (E) 
and non-structural protein 1 (NS1) gene region of dengue virus 
genome has shown to reflect evolutionary relationships and geographic 
origins of the viral strains. This approach was used to demonstrate an 
association between the introduction of two distinct genotypes of 
dengue type 2 virus and the appearance of dengue hemorrhagic fever 
in the Americans (Rico-Hesse et al., 1997). Combinations of the 
dengue viral strains makes concurrent (multi-strain) infections or 
reoccurring dengue infections possible, especially in areas with high 
prevalence of dengue virus. In such cases, competitive strain 
displacement occurs when a more virulent strain of the virus competes 
with a less virulent strain, resulting in an alteration in strain frequency. 
Thus, the more virulent strain can replicate and disseminate faster in 
the vector and host decreasing the extrinsic incubation period. 





Figure 1.1: Phylogenetic tree of DENV serotypes  
The evolutionary tree of the different serotypes of dengue virus was derived from E 
protein gene nucleotide sequences of sylvatic and endemic or epidemic DENV strains 
(Wang et al. 2000). 





 Phylogenetic and epidemiological analyses suggest that more 
virulent genotypes are now displacing those that have lower 
epidemiological impact (Wang et al. 2000; Cologna et al., 2005). Some 
genotypes Southeast Asia and India have been associated with the risk 
of causing severe dengue hemorrhagic fever (DHF) and dengue shock 
syndrome (DSS) (Rico-Hesse, 2003). In view of that, understanding the 
virulence and attenuation of the virus is key for development of 
vaccines and antiviral agents.  
 
 
1.3 DENV Epidemiology and Global Consequence 
Dengue epidemics can have a significant economic and health 
toll as it plays a leading role in public health threat in the tropical and 
subtropical regions (Wilder-Smith et al., 2010). According to WHO, the 
global incidence of dengue has increased dramatically to about 30-fold 
over the past 50 years and about 2.5 billion people forming 40% of the 
world´s population are now at risk of the disease (Figure 1.2). Each 
year, WHO estimates about 50-100 million DENV infections worldwide. 
Approximately, 500,000 people with severe dengue are hospitalized 
annually, of whom 2.5% die (WHO, 2012).  
Increase in dengue viral infection, pandemic and severity, may 
largely be attributed to factors such as increased urbanization and 
population density, inadequate housing and public health systems, 
poor vector control, climate change, viral evolution and increased 




international travel to endemic areas. This has led to the geographic 
spread, evolution, overlap and interaction of all four dengue viral 
serotypes (Endy et al., 2010). 
 
Figure 1.2: World map showing countries and areas where dengue viral infection has 
been reported or at risk of dengue pandemic (World Health Organization, 2012) 
                 Risk of dengue infection                                      
 Areas with no known infection 
 
 
 Spatial and temporal patterns of dengue prevalence are likely 
driven by other factors including the immune status of human hosts, 
their age, virus traits, and environmental variables including aspects of 
climate such as levels of precipitation (Rico-Hesse et al., 1997).  
 
 




1.4 Dengue Virus Pathogenesis and Host Immune Response 
1.4.1 Host Immune Response 
 During dengue viral infection, natural killer (NK) cells and 
dendritic cells (DCs) of the innate system are able to detect and induce 
the release of antiviral cytokines to control viral replication (Trinchieri, 
1989). DCs detect and displays processed peptides of the invading 
pathogen for recognition by T cells of the adaptive immune system 
(Lindahl et al., 1976; Schroder et al., 2004; Welsh et al., 2012). 
Activated CD4+ T helper cells secrets antiviral cytokines that also 
activates the immune components to fight the infection whilst activated 
CD8+ T cytotoxic cells also recognize and kill DENV infected cells 
(Lindahl et al., 1976; Schroder et al., 2004; Welsh et al., 2012). B cells 
on the other hand produces antibodies (Abs) against DENV, some of 
which play critical roles in neutralizing homologous DENV against re-
infection.  
 Activation of the complement system through the mannose 
binding lectin pathway triggers several events which reduced DENV 
infection (Shresta, 2012). The release of antiviral cytokines such as 
type 1 interferon (IFNs) plays a critical role to limit spread of infection 
(Schroder et al., 2004). The role of IFN includes up regulating the 
expression of class I and II major histocompactibility complex (MHC) 
thereby activating the function of T helper cells (Lindahl et al., 1976; 
Schroder et al., 2004; Welsh et al., 2012).  
 




1.4.2 Dengue Virus Pathogenesis 
                To successfully survive in the host, flaviviruses such as 
DENV has been shown to inhibit some important innate immune 
elements like type 1 IFN signaling and in the phosphorylation of some 
kinases (Jones et al., 2005; Ho et al., 2005). DENV NS5, NS2A, NS4A 
and NS4B proteins have been found to serve as antagonist for type 1 
IFNs (Munoz-Jordan et al., 2003, 2005; Liu et al., 2004;  Ashour et al., 
2009) with NS5 serving as the most potent inhibitor of IFN signaling by 
targeting and degrading several components of the signaling pathway 
such as STAT2 (Ashour et al., 2009).  
            Studies have shown that inhibition of IFN signaling by NS5 
occurs in a species specific manner due to the inability of NS5 to bind 
and degrade STAT2 in mice, resulting in limited host tropism of DENV 
to humans and non-human primates (Ashour et al., 2009; Perry et al., 
2011). NS5 also induces cytokine production such as interleukin 8 (IL-
8)  transcription and secretion resulting in the recruitment of several Fc 
receptor bearing cells to the infection site thereby enhancing the 
spread of the virus due to its special ability to infect neighboring cells 
(Medin et al., 2005).  
  
1.4.3 Antibody Induced Enhancement of Dengue Virus 
 The mechanism in which DENV successfully survive in the host 
cell resulting in severe complications is not completely resolved. 
Structural differences in DENV strains have been proposed to play a 




role in the differing abilities through which the virus infects and causes 
severe disease complications (Diamond et al., 2000; Vaughn et al., 
2000). It has been hypothesized that some increased severity and 
complications in DENV secondary infection is caused by antibody-
dependent enhancement (ADE) (Halstead et al., 1977; Kliks et al., 
1989; Modhiran et al., 2010).  
 When sub-neutralizing antibodies directed to one DENV 
serotype from previous infection binds to another DENV serotype upon 
secondary infection, DENV-Ab complex from the secondary infection 
binds to Fc receptor bearing myeloid cells (Halstead et al., 1977; 
Boonnak et al., 2008; Balsitis et al., 2010). This results in partial cross 
reactivity enhancing viral uptake by these cells (KliKs et al., 1989; 
Modhiran et al., 2010).  
  Increased viral replication in Fc receptor bearing cells could 
also be caused by antigenic sin whereby, a potentially harmful T helper 
cell response rather activates the immune cells to previous DENV 
serotype (primary infection of one serotype) instead of the current 
infecting DENV serotype (secondary infection of a different serotype) 
(Rothmanm 2004; OhAinle et al., 2011). Thus, Abs produced during 
DENV infection with one serotype does not guarantee viral 
neutralization upon reinfection with the other serotypes. The exact 
mechanism through which antibodies increase DENV disease severity 
is not fully established.  
 This indicates that with more cells infected, more virions would 
be produced, leading to higher titres of virus in the blood and higher 




viremias are known to be correlated with immunopathogenesis 
resulting in an increased risk for DHF and DSS (Rico-Hesse, 2007). 
ADE is also correlated to suppression of innate immune response 
through inhibition of pro-inflamatory cytokine responses and IFN 
production (Modhiran et al., 2010). This process could explain DENV 
disease complications in infants whereby low neutralizing maternal Abs 




1.5 Clinical Signs and Symptom 
  Dengue viral infection results in a broad spectrum of outcome 
ranging from a mild or nonspecific febrile illness known as classical 
fever occurring within 5 to 7 days to a more severe form known as 
dengue shock syndrome DSS. WHO has recently classified dengue 
viral infection into Dengue without warning signs, Dengue with warning 
signs and Severe Dengue (WHO, 2009). Some symptoms of Dengue 
with warning signs includes: headache, fever, retro-orbital pain, chills, 
back pain, loss of appetite, rash, nausea and vomiting (WHO, 2009).
 The disease then progresses to a toxic phase known as Dengue 
without warning signs. This involves a recurring fever known as dengue 
hemorrhagic fever DHF which results in a primary pathology of 
increased microvascular permeability leading to fluid loss from the 
systemic circulation. In some cases, DHF is also characterized by 
hepatomegaly, high fever and signs of circulatory failure (WHO, 2009).  




 DSS is the most severe form of the disease which could as well 
lead to death. Severe Dengue has some clinical manifestations like 
organ failure and internal haemorrhage. While the 1997 WHO 
classification used the terms DHF and DSS, the 2009 classification 
scheme tried to encompass other observed outcomes in dengue 
patients. While most severe cases had shock, others had internal 
hemorrhage or organ dysfunction, which have been reported to occur 
without plasma leakage.  
.  
 
1.6 Life Cycle of Dengue Virus 
 Dengue viruses have been found to infect fibroblasts, 
hepatocytes, endothelial cells, epithelial cells, and some immune cells 
in vitro (Upanan et al., 2008). The life cycle of dengue can be 
summarized into seven steps (Figure 1.3). This involves attachment 
and endocytosis, membrane fusion, translation, replication, assembly, 
maturation and exocytosis. The virus enters the cell through receptor-
mediated endocytosis which involves an initial attachment and 
formation of fusion complex using its glycoprotein envelope (E) with 
host cell surface receptor molecule such as heparan sulphate (Putnak 
et al., 1997), macrophage mannose receptor (Miller et al., 2008) and 
dendritic cell-specific intercellular adhesion molecule 3-grabbing non-
integrin (DC-SIGN) (Tassaneetrithep et al., 2003). 
 






Figure 1.3: Schematic representation of dengue virus life cycle in host cell 
 
The pH of each compartment are indicated in coloured boxes. (Reprinted from Anti viral 
research, volume 80(1), Rushika Perera, Mansoora Khaliq and Richard J. Kuhn, Closing 
the door on flaviviruses: Entry as a target for antiviral drug design, pages 11-22, Copyright 
(2008), with permission from Elsevier) 
 
 
 Endocytosis of DENV occurs either by clathrin-mediated 
pathway, direct fusion into cell membrane or antibody recognition 
(Peng et al., 2009; Hase et al., 1989a). The virus uncoats intracellularly 
by the acidification of endosomes which triggers an irreversible 
trimerization of glycoprotein E promoting its fusion with endosomal 
membranes. This subsequently results in the release of viral RNA from 
the nucleocapsid (C) into host cytoplasm where DENV positive (+) 
single strand (ss) RNA is then translated (Mukhopadhyay et al., 2005).  




          Translation into a single polyprotein is initiated by the 5´ cap 
structure on the RNA promoting assembly of eukaryotic initiation 
factors (eIFs) which then recruits ribosomes to the viral RNA. Poly-A 
binding protein subsequently interacts with the 3´ UTR end of DENV 
RNA and eIFs resulting in protein synthesis. The post translational 
processing proceeds through a combination of signal peptidases, the 
viral serine protease, and additional cellular proteases (Lindenbach 
and Rice, 2003).  
           DENV RNA strand to be replicated is cyclized by 
complementary 5´-3´UTR conserved sequences followed by 
attachment to the replication complex where RNA synthesis is initiated. 
Viral non-structural (NS) proteins actively replicates genomic RNA 
producing a complementary minus (-) ssRNA by the initial formation of 
a replicative intermediate known as double-strand (ds) RNA (Uchil, 
2003). - ssRNA then serves as a template for replication to produce 
several copies of genomic + ssRNA (Westway, 1987; Bartholomeusz 
and Thompson, 1999). NS5 is known to play a major role in viral RNA 
synthesis through de novo initiation and elongation process 
(Nomaguchi et al., 2004; Filomatori et al., 2006). 
           Viral assembly and formation of immature virus particles occurs 
at the endoplasmic reticulum (ER) membrane whereby one copy of 
genomic RNA interacts with several copies of capsid structural protein 
forming nuclear capsid. The nuclear capsid is enveloped by the 
precursor glycoprotein membrane-envelope complex (prM-E) forming 




an immature virus that buds off into the rough ER lumen (Allison et al., 
1995).  
 Although these particles contain genomic RNA and the three 
structural proteins (membrane precursor glycoprotein, envelope and 
nuclear capsid), the newly formed viral particle is non-infectious. This is 
because; it cannot induce host-cell fusion since the prM-E needs to be 
further processed (Murray et al., 1993). The immature viral particles 
are then transported through golgi apparatus where the acidic 
environment of the trans-Golgi network (TGN) furin-mediated cleavage 
of membrane glycoprotein and envelop results in viral maturation. 
Mature virus then migrates into the cytoplasm which is then released 
from the cell through exocytosis to infect other cells. 
 
 
1.7 Virus Morphology 
 The virus is made up of ~180 copies of membrane and envelope 
proteins organized with an icosahedral arrangement (Zhang et al., 
2004). Electron micrographs of the viral particle (Figure 1.4) reveals 
that, DENV are characterized by a relatively smooth surface, with 
diameter of ~50 nm, and an electron-dense core surrounded by a 
homodimer envelope protein with its long axis parallel to the membrane 
protein and its arranged into 30 organized rafts (Rey et al., 1995b, 
Zhang et al., 2004). DENV glycoprotein E forms icosahedral scaffolds 
and participates in the membrane fusion process (Lescar et al., 2001; 
Allison et al., 2001).  







Figure 1.4: Structure of matured E protein on viral particle surface 
Fusion peptide is shown green whiles the E protein domain I, II and III are indicated in 
red, yellow and blue colours respectively. The scale bar represents 100 Å. (Reprinted 
from Cell, volume 108. Richard J. Kuhn, Wei Zhang, Michael G. Rossmann, Sergei V. 
Pletnev, Jeroen Corver, Edith Lenches, Christopher T. Jones, Suchetana 
Mukhopadhyay, Paul R. Chipman, Ellen G. Strauss, Timothy S. Baker, James H. 
Strauss: Structure of Dengue Virus: Implications for Flavivirus Organization, 






The nuclear capsid protein consists of 100 amino acids and it is 
~25 - 30 nm in diameter.  The plus-sense RNA genome is enclosed by 
the capsid (C) protein. The membrane and envelope protein consists of 
75 and 495 amino acids respectively. The viral envelope glycoprotein is 
made up of three domains namely the central domain I located at the N 
terminus, elongated dimerization domain II and lastly, the receptor 
binding domain III (Zhang et al., 2004).  
 
 ¨ 




1.8 Dengue Virus Genome 
 Dengue virus consists of a single stranded non-segmented 
positive sense (+) RNA genome which is ~11 kb in length. It has a 
conserved type I 5´ cap m7GpppAmG structure which is essential for 
RNA stability but lacks a poly- (A) at its 3′-end (Wengler and Wengler, 
1981). Currently, the 4 serotypes of DENV have been found to possess 
about 67-73% similarity at the nucleotide level and 69-78% at the 
amino acid level. The viral genome contains one open reading frame 
(ORF) that is flanked by a highly structured and conserved 5´ and 3´ 
untranslated regions (UTRs) (Figure 1.5 B).  
The ORF has a ~10,200 nucleotide sequence that encodes 
polyproteins (~3400 amino acids) during translation. The proteins 
undergo post translational cleavage to produce three structural (capsid, 
membrane protein and envelope) and seven non-structural proteins 
(NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5) (Figure 1.5 C). The 
conserved 5´ and 3´ UTRs are made up of ~100 and 400 nucleotides 
respectively. The UTRs have been found to be essential for translation, 
RNA replication, regulation and severity of infection (Cahour et al., 
1995; Kinney et al., 2005).  
The predicted 5´UTR has three structured regions known as 
stem-loop (SL) A, SLB and SL capsid hairpin (cHP) with two conserved 
sequences at the 5´ upstream AUG region (UAR) on SLB and 5´ 
cyclization sequence (CS) located at the cHP region near the 
beginning of the ORF. SLA serves as a promoter for NS5 RdRp 
followed by SLB which contains the AUG capsid initiation codon 




(Brinton and Dispoto, 1988). The cHP is required for the enhancement 




Figure 1.5: Schematic diagram of Dengue virus genome 
 
Shown here is, A) The  5´-3´RNA circularization of UAR and CS of the viral genome. 
B) Conserved structural and sequence elements within the 5´-3´ UTRs C) Structured 
and non-structured polyprotein translated from ORF (Reprinted from antiviral 
research, volume 77, Karl Maramorosch, Aaron J. Shatkin and Frederick A. Murphy,  





The 3´ UTR is also made up of three regions namely the 
variable region located at the termination site, core region which 
contains CS and predicted to form secondary structures called 




pseudoknot (Hahn et al., 1987) and terminal regions which has SLs. 
The 3´ structured SLs are required for efficient translation and promote 
binding of RNA to host polysomes whiles the function of CS located at 
the 3´ end of the ORF is yet unknown. The 3´ UTR also has conserved 
sequence elements at the 3´UAR which is complementary to 5´UAR 
(5´-3´UAR) and 3´CS complementary to 5´CS (5´-3´CS). Hybridization 
of 5´ 3´ complementary sequences is involved in RNA circularization 




1.9 Virus Structural Proteins 
1.9.1 Capsid Protein 
 The capsid (C) protein is ~11kD in size and has a high basic 
property. It is the first protein to be translated and mostly found in the 
cytosol and nucleus of infected cells (Samsa et al., 2009). It has a short 
hydrophobic region which is flanked by an N and C terminus. The C-
terminal has been found to serve as a signal peptide required for the 
translocation of the membrane protein which is later cleaved by NS2B–









1.9.2 Membrane Protein 
 The membrane (M) protein is ~8 kD in size and it is initially 
linked with a 91 polyprotein glycosylated precursor fragment leading to 
the formation of precursor M protein (prM). The prM is ~26kD in size 
and has a furin cleavage site. The pr segment of M protein is known to 
stabilize the glycoprotein envelope (E) through the formation of a 
heterodimer complex required for the folding of E protein (Lorenz et al., 
2002). Viral maturation occurs upon cleavage and dissociation of pr 
peptide segment from the M protein by host furin which occurs shortly 




1.9.3 Glycoprotein Envelope  
 Dengue viral envelope (E) is a surface protein of ~53 kD in size. 
The proteins are differentially glycosylated with respect to DENV 
serotype, host target cell and their E receptor binding complex (Lozach 
et al., 2005; Pokidysheva et al., 2006). The glycosylation has been 
implicated in virion attachment to host cell receptor and endosomal 
fusion of the virus target cell membrane (Lozach et al., 2005; 
Pokidysheva et al., 2006). The E proteins also function as the main 
antigenic determinant of the virus resulting in its principal target for 
neutralizing antibodies (Richman et al., 2002). The protein exists in 
three different conformations namely; prM-E heterodimer present in the 




immature virus particle, E homodimer formation in the mature virus 
particle and E trimer which expose the fusion peptide and mediate 






1.10     Virus Non-structural Proteins 
1.10.1   NS1 
 It is the first of the seven non-structural proteins to be translated 
and has a size of ~46 kD. In addition to the viral E protein, NS1 has 
also been found to be the only non-structural protein associated with 
protective immunity. NS1 antigen has been found to correlate with 
levels of viremia and could serve as a promising tool in the early 
diagnosis of DENV infection (Libraty et al., 2002b; Datta and Wattal, 
2010). Studies has also shown that NS1 colocalize in vesicle packets 
(VPs) thereby forming a component of the viral replication complex 
(Westaway et al., 1997). The proteolytic release of NS1 from NS2A is 
accomplished by an unknown membrane bound host protease which 
has been proposed to be present in the lumen of the ER (Flagout and 
Markoff, 1995). It has been proposed that interactions of NS1 with 








1.10.2     NS2A 
 NS2A is a relatively small membrane associated protein with a 
size of ~22kD. NS2A is known to contain the required recognition 
sequence for host enzyme cleavage from NS1 (Flagout and Markoff, 
1995). The hydrophobic residues of NS2A have been found play an 
essential role in the assembly and release of viral particles (Leung et 
al., 2008). NS2A contains transmembrane domains and is also 
associated with components of the replication complex and binds to 3′ 




1.10.3     NS2B 
 It is the smallest of all non-structural proteins with a size of ~14 
kD. NS2B has been identified to possess proteolytic activities which 
are required for the removal of peptide segments from viral proteins 
(Falgout et al., 1991). The hydrophobic membrane associated protein 
has a conserved central hydrophilic residues that acts as a cofactor by 
forming a complex with the serine proteinase in NS3 (NS2B-NS3) 
involved in catalyzing the cis cleavage of NS2A and NS2B (Jan et al., 










1.10.4     NS3 
 It is the second largest protein with a size of ~70kD.  NS3 is 
known to possess several enzymatic properties basically required in 
RNA synthesis and polyprotein processing. NS3 is also found to 
colocalize in VPs thereby forming a component of the viral replication 
complex (Westaway et al., 1997). The N-terminus of NS3 has serine 
protease activity (Bera et al., 2007; Perera and Kuhn, 2008) whiles the 
C-terminus has been shown to have RNA helicase, 5´RNA 
triphoshatase (RTPase) and NTPase activities (Luo et al., 2008; Perera 
and Kuhn, 2008).  
The protease property of NS3 is essential for cleaving 
NS2A/NS2B, NS2B/NS3, NS3/NS4A, NS4B/NS5 and C protein/signal 
sequence sites (Bera et al., 2007; Clum et al., 1997; Amberg et al., 
1994; Nestorowicz et al., 1994; Preugschat and Strauss, 1991). The 
efficiency and stabilization of the serine protease is attained when 
coupled with NS2B (Westaway et al., 1997; Jan et al., 1995). The NS3 
RTPase activity has been suggested to be required for 
dephosphorylation of 5´RNA end before addition of the type I cap 
structure by NS5 MTase (Wengler, 1993). NS3 is also required for the 
stimulation of NS5 replicative activities. The helicase activity of NS3 is 











1.10.5    NS4A 
 It is a hydrophobic protein of ~16 kD in size. NS4A has been 
found to be essential for membrane rearrangements and reassembling 
of virus-induced structures (Miller et al., 2007; Miller et al. 2006). NS4A 
has also been shown to colocalize in VPs membrane structure thereby 
forming a component of the viral replication complex and its interaction 
with NS1 is essential for viral replication (Westaway et al., 1997; 
Mackenzie et al., 1998). Proteolytic cleavage of NS4A from NS3 during 
post translational processing in the cytosol is carried out by the serine 
protease.  
 
1.10.6      NS4B 
 It is a hydrophobic protein of ~27 kD in size. Translocation of 
NS4B to the lumen of the ER is made possible by the signal sequence 
attached to the C-terminal region of NS4A. Proteolytic cleavage of 
NS4B from NS5 during post translational processing is carried out by 
the viral serine protease. NS4B forms a component of the viral 
replication complex (Miller et al., 2007; Miller et al. 2006). It dissociates 
NS3 from ssRNA during replication by promoting the unwinding of 
coiled RNA and replicase activity (Lindenbach and Rice 1999; 








1.10.7   NS5 
 The focus of this research study is on DENV NS5. This protein 
is multifunctional, multidomain and the largest of all nonstructural 
proteins with a size of ~105 kD. The NS5 region on DENV genome 
(Figure 1.6) is the most conserved in all flaviviruses with more than 
70% sequence identity across the four DENV serotypes, and also in 
other flaviviruses, making it an attractive drug target for antiviral 
interventions (Rico-Hesse, 1990; Malet et al., 2008; Zou et al., 2011). 
NS5 is known to possess two enzymatic properties which serves as the 
major enzymes required in viral RNA replication. The protein consists 
of 900aa with residues 1-272 at the N-terminal domain encoding both 
S-adenosyl methionine methyltransferase and guanylyltransferase 
activity (Koonin, 1993; Egloff et al., 2002; Dong et al., 2008; Issur et al., 
2009; Yap et al., 2010). Whereas residues 273–900 located at the C-
terminus is known to possess a RNA-dependent RNA polymerase 
(RdRp) activity (Koonin, 1991; Tan et al., 1996; Guyatt et al., 2001; 
Yap et al. 2007).  
The X-ray crystal structures of both enzymatic domains of NS5 
in DENV serotype 3 have been determined (Yap et al., 2010; Yap et al. 
2007). But on the other hand, the X-ray crystal structure of the full-
length (FL) DENV NS5 has not been solved. Hence, how 
methyltransferase (MTase) and RdRp domains are arranged with 
respect to one another remains elusive. This could be due to the 
flexibility of the short interdomain linker region (IDLR) located between 
the MTase and RdRp domain (Bollati et al., 2010; Egloff et al., 2002). 




Even though NS5 is known to be part of the viral replication complex 
whereby it interacts with NS3 during RNA replication, experiments 
have demonstrated the localization of NS5 in the cell nucleus (Buckley 




Figure 1.6: Simplified diagram of DENV RNA genome indicating NS5 RdRp 









1.10.7.1    Role of NS5 in DENV Pathogenesis 
 Aside its key role in RNA replication, NS5 has the ability to alter 
some key mechanisms responsible for host immune responses. NS5 is 
known to be associated with viral pathogenesis through nucleus 
trafficking by its nuclear localization sequence (NLS) and also 
activation of interleukin-8 (IL-8) cytokine production and secretion. But 
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the main mechanism through which it localizes in both the nucleus and 
cytoplasm contributing to its pathogenic effect remains to be unraveled. 
As previously discussed (Section 1.4.2), NS5 is as well known to 
interfere with IFN signaling and in the phosphorylation of host cell 
kinases (Khabar et al., 1997; Medin et al., 2005; Koo et al., 2006; Pryol 






1.10.7.2          NS5 Methyltransferase  
 NS5 MTase is responsible for the N-7 and 2´-O methylation of 
DENV viral RNA resulting in the formation of GTP type 1 cap structure, 
m7GpppAm (Cleaves and Dulbin, 1979; Wengler and Wengler, 1981). 
The RNA capping process is initiated by the addition of a guanine 
monophosphate (GMP) moeity to the 5´ end of the viral RNA (Wei and 
Moss, 1977). Followed by N-7 methylation of guanine by guanine-N7-
methyltransferase and 2´-O methylation on the first transcribed 
nucleotide (adenine) by nucleoside-2´-O-methyltransferase (2´-O-
MTase) (Dong et al., 2008; Ray et al., 2006; Egloff et al., 2002). This 
capping structure is required for RNA replication, mRNA stability and 
protein translation during viral infection (Furuichi and Shatkin, 2000; 
Shuman, 2001; Dong et al., 2008). Studies conducted by Selisko et al., 
2010 showed that the efficiency of the methylation of both N-7 and 2´-
O are independent.  
    




1.10.7.3 NS5 RNA-dependent RNA Polymerase  
 DENV NS5 RdRp is currently one of the main targets for 
development of vaccine and antiviral therapeutics because its enzyme 
activity is critical for viral propagation (Blaney et al., 2004; Blaney et al. 
2008). RdRp is able to initiate RNA replication in a de novo manner 
without the need for a viral RNA primer (Ackermann & Padmanabhan, 
2001; Selisko et al., 2006). De novo initiation and elongation are the 
two main processes required in the RNA synthesis (Dutartre et al., 
2005; Selisko et al., 2006; Choi and Rossmann, 2009).  
 Replication begins by RdRp binding to the 5´SLA region of viral 
RNA. Studies have shown that interaction between RdRp and SLA 
promoter region at the 5´UTR end (Figure 1.5) is important for in vivo 
and in vitro replication (Filomatori et al., 2006; Yu et al., 2008; Lodeiro 
et al., 2009). However, the negative strand RNA synthesis is initiated 
by the interaction of RdRp with 3´TR of 3´UTR (Figure 1.5). RNA 
template with specific initiation nucleotide, RdRp, an initiation NTP and 
a second NTP is required for the de novo initiation process (van Dijk et 
al., 2004; D’Abramo et al., 2006).   
 In general, Flavivirus de novo initiation begins by the addition of 
the initiating NTP to the initiation site of the viral RNA template (van 
Dijk et al., 2004; D’Abramo et al., 2006; Choi and Rossmann, 2009; 
Selisko et al., 2012). The initiating NTP provides a 3’ hydroxyl group 
required for the binding of the second NTP substrate resulting in the 
formation of a phosphodiester bond (van Dijk et al., 2004; D’Abramo et 
al., 2006; Choi and Rossmann, 2009). The NTP is held in place 




through the interaction of its triphosphate group with the two metal ions 
coordinated by the presence of the GDD motif in the RdRp (Choi et al., 
2006; Choi and Rossmann, 2009).  
The de novo initiation process is then followed by the RNA 
elongation. During elongation, the RdRp changes to a different 
conformation whereby the C-terminal is opened resulting in the 
translocation of template-nascent RNA (Ferron et al., 2005).  RNA 
elongation process is relatively fast and processive as compared to de 
novo initiation which is rather slow and abortive leading to formation of 
short RNA products (Dutartre et al., 2005; Selisko et al., 2006). 
 
 
1.10.7.4 Structure of NS5 RNA-dependent RNA Polymerase 
 The crystal structure of Flavivirus RdRp, using DENV 3 as an 
example, adopts a right hand conformation (Figure 1.7) consisting of a 
finger, palm, and thumb subdomains (Yap et al., 2007; Malet et al., 
2007; Perera and Kuhn, 2008). The interdomain region mediates 
interactions between the NS5 and NS3 proteins (Johansson et al., 
2001). The finger subdomain contains two NLS promoting the transport 
of NS5 protein to the host cell nucleus (Brooks et al., 2002; Yap et al., 
2007; Malet et al., 2008; Bollati et al., 2010).   
 The palm serves as the catalytic domain of the enzyme, having 
the most conserved sequence across all four serotypes and in other 
flaviviruses as well. It contains the RNA template binding channel and 
the NTP channel (Yap et al., 2007; Malet et al., 2008; Choi and 




Rossmann, 2009). The catalytic domain also has a highly conserved 
amino acid residues Glycine-Aspartate-Aspartate (GDD) motif (Figure 
1.8) that coordinates Mg2+ and Mn2+ metal ions essential for 
polymerase structural flexibility, catalytic activity and nucleotide 
incorporation (Yap et al., 2007; Bougie and Bisaillon, 2009; Choi and 




Figure 1.7: Ribbon structure of the closed conformation of DENV 3 NS5 RdRp  
The NLS, finger, palm and thumb subdomains are indicated in yellow, blue, green 
and pink respectively. Figures (A) and (B) are different (clockwise and anticlockwise) 
views of RdRp. The N and C terminal are displayed whilst the priming loop as well as 
two zinc ions located at the finger and thumb region is also displayed in orange 
colour. C) Shown here is the enlarged view of RdRp domain indicating structures of 
nine different amino acid residues (F398, K401, F485, N492, G604, Y606, N609, 
D663, W795) lining the catalytic sites and were mutated to Ala.  
 




 The thumb region has a C-terminus that interacts with both 
finger and palm domains resulting in the closed conformation of RdRp 
during de novo initiation. This is to restrict access to the template 
binding channel thereby preventing dsRNA binding to RdRp active site 
and allow for only ssRNA accommodation (Hong et al., 2001; Choi et 
al., 2004). The RdRp open conformation is required during elongation 
process to accommodate the dsRNA template-primer product 
(Nomaguchi et al., 2003; Ranjith-Kumar et al., 2006). The dsRNA 
product exits the active site via the front of the polymerase (Butcher et 
al., 2001; Ferrer-Orta et al., 2004).   
 The presence of priming loop stabilizes and provides de novo 
initiation platform for the binding of the initiating or priming nucleotide 
(Yap et al., 2007; Malet et al., 2008). The priming loop points from the 
thumb towards the active site in the RdRp enzyme. Presence of zinc 
ion is responsible for the regulation of conformational changes between 
the closed and open RdRp forms (Yap et al., 2007; Malet et al., 2008). 
The function of the first zinc ion located at the fingers is coordinated by 
residues Cys-446, Cys-449, His-441 and carboxylate group of Glu-437 
whilst the second zinc ion located at the thumb subdomain is 
coordinated by His-712, His-714, Cys-728 and Cys-847 (Selisko et al., 
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Figure 1.8: DENV 1 to 4 NS5 RdRp construct sequence alignment 
Residue numbering and structural assignment are based on DENV 3 RdRp structure. 
The selected amino acid residues (F398, K401, F486, N492, G604, Y606, N609, 
D663, W795) for mutageneic analysis are in turquoise. The conserved motifs are 
coloured in grey and the GDD motif are in red box. The NLS and priming loop are 
marked with black arrow and indicated in yellow and pink respectively. The amino 
acid residue numbering is labeled with asterisks with intervals of 20 residues. DG1 
represents DENV serotype 1 from Hawail strain, DG2 represents DENV serotype 2 
from TSV01 strain, D3 represents DENV serotype 3 from SGEH1 strain and DG4 
represents DENV serotype 4 from MY22713 strain. 
 
 
 Since there has not been any major success with mosquito vector control and currently, there are no vaccines or therapeutic measures available to control the virus or disease, an in-depth understanding                       




1.11     Rationale 
              Currently, there has not been much major success with Aedes 
sp. mosquito vector control in most tropical and sub tropical countries. 
Also, there are no vaccines or therapeutic measures available to 
control the virus or disease. An in-depth understanding of molecular 
and cellular biology of DENV lifecycle is required to develop antiviral 
agents towards the control of dengue disease. As compared to the 
other DENV proteins, NS3 and NS5 are known to contain all viral 
enzymatic activities as previously stated. We have also discussed the 
role of NS5 RdRp been essential in viral propagation, making it the 
most conserved amongst all DENV serotypes (Figure 1.8) and 
Flavivirus (Ackermann and Padmanabhan, 2001).  
             Moreover, enzymes have been considered the most excellent 
target for pharmacological interventions due to their significant role in 
many disease pathogenesis. They currently form about 40% of drug 
targets worldwide (Rask-Andersen et al., 2011). The NS5 RdRp 
enzyme have been considered as one of the most interesting targets 
for drug discovery since its polymerase activity is essential for the 
synthesis of dengue viral RNA, and most importantly, the enzyme has 
no equivalent in the human host cell (Cerutti and Casas-Mollano, 2006).  
            Exploration for DENV RdRp antivirals are in its early phase. 
RdRp structural determinant through crystallography have made it 
promising to help in unravelling their biological processes including 
catalytic activity, mode of action and their binding sites. Thereby, 
enabling chemists to design small molecules for selective inhibition of 




DENV enzyme required for viral pathogenesis (Malet et al., 2008; 
Noble et al., 2010). NS5 RdRp inhibitory compounds may either 
directly inhibit the enzyme activity or its interaction with RNA and other 
proteins. The two classes of compounds known to inhibit polymerase 
activities are either nucleoside or non-nucleoside inhibitors (Malet et al., 
2008). Nine amino acid residues located within DENV NS5 RdRp 
domain (as shown in Figure 1.7; 1.8) have been identified by X-ray 
crystallography to interact with two non-nucleoside inhibitors from NITD 
namely; NITD567 and NITD329 (Table 1.1).  
 
Table 1.1: Interaction of DENV NS5 RdRp amino acid residues 






of residue in  
DENV 1, 2, 3, 4 
serotypes 




1 Phe399 conserved pi-pi Ala 
2 Lys402 
 
conserved H-bond with sulfonamide Ala 










via water molecule (to 
backbone in Gly607 and 
side chain of Gly604) Ala 
6 Tyr607 conserved van der waal forces Ala 
7 Asn610 
conserved side chain with carboxylic 
acid Ala 
8 Asp664 conserved backbone and side chain Ala 






of residue in  
DENV 1, 2, 3, 4 
serotypes 







9 Trp796 conserved backbone O Ala 
 
 




            These two compounds have been found to inhibit DENV NS5 
RdRp de novo initiation and elongation activities in vitro as shown in 
the IC50 results (Table 1.2; "NITD unpublished data"). In view of that, 
we decided to characterise the nine amino acid residues interacting 
with the two compounds (Figure 1.7) within DENV NS5 RdRp binding 
pocket. This was to understand their biophysical, biochemical and 
biological importance during the viral RNA replication. 
 
Table 1.2: IC50 results from NITD567 and NITD329, NITD  
Inhibitor 
NS5 RdRp activity  
IC50 (µM) 
De novo Elongation 
NITD567 4.22 5.22 
NITD329 1.17 2.10 
 
 
1.11.1 Objectives of Study 
        The aims of this research study are: 
1. To assess the drug-ability and relevance of the binding pocket of 
NITD329 and NITD567 in the DENV NS5 RdRp. 
2. To characterize the mechanism of action of these inhibitors by 
performing mutagenesis experiments  
3. To study the polymerase-inhibitor interactions  
4. To assess the relevance of the inhibitor binding pocket for in 
vitro polymerase activity and  
5. To assess the relevance of the inhibitor binding pocket for 
replication fitness in the context of the infectious virus. 





MATERIALS AND METHODS 
2.1 Cloning of pET28a-D4MY01-NS5-22713 NS5 Mutants using 
Site-directed Mutagenesis 
 To make constructs of the various alanine mutations of RdRp 
domain on DENV 4 NS5 as indicated in Table 1.1, template plasmid 
pET28a-D4MY01-NS5-22713 bearing DENV 4 FL NS5 (generous gift 
from Niyomrattanakit et al., 2010) was used to perform site-directed 
mutagenesis (SDM) with Quik Change II XL SDM kit (Stratagene, 
U.S.A.) according to manufacturer´s protocol. A 50 µl reaction mixture 
comprised 1 µl of 15 - 50 ng/µl DNA template, 5 µl of 10x reaction 
buffer, 1.25 µl of 10 µM FOR/REV Primers, 1 µl of 10 mM dNTPs, 3 µl 
of DMSO, 1 µl of 2.5 U/µl PFU DNA polymerase. Primers for pET28a-
D4MY01-NS5-22713 mutants (AITbiotech, Singapore) are shown in 
Table 2.1 below. Cycling conditions were; initial denaturation: 95 °C for 
3 min; 18 cycles of denaturation: 95 °C for 1 min; annealing: 55 °C for 1 
min and extension: 68 °C for 10 min using C1000 thermal cycler (Bio 
Rad, Singapore). PCR products were further digested with 1 µl 10 U/µl 
DpnI enzyme for 1 hr at 37 °C.  
 QIAquick PCR purification kit (QIAGEN, U.S.A.) was used to 
purifiy the mutated plasmids before transformation into XL1-Blue 
supercompetent cells (Stratagene, U.S.A.). 200 µl of each 
transformation  




Table 2.1: DENV 4 Mutants Primers for Site-specific Mutation in 













































































Nomenclature for the mutant primers are described as: dengue virus serotype 4 (D4), 
non-structural protein 5 (NS5) and the alphabets preceding each numbers are 
standard single amino acids nomenclature for each amino acid residue that was 
mutated to alanine (A). For instance W796A indicates tryptophan (W) amino acid at 
position 796 was mutated to alanine. FOR and REV represents the "forward" and 
"reverse" primers respectively The primer sequence has been designated with the 
standard three codon from their 5´ to 3´ end with the red font indicating position of the 
mutated region. 
 




reaction was grown on Luria-Bertani (LB) agar plate containing 30 
µg/ml Kanamycin (Kan) and incubated overnight (O/N) at 37 °C. 
Positive clones were inocculated into 4 ml LB broth + Kan and grown 
O/N at 37 °C with shaking at 220 revolutions per minute (rpm). Plasmid 
DNA was isolated and purified using QIAprep Spin Miniprep Kit 
(QIAGEN, U.S.A.). Construct sequences were verified by DNA 




2.2 Expression and Purification of DENV 4 FL NS5 Mutant 
Protein Histidine-tagged  
2.2.1 Expression of DENV 4 FL NS5  
                     pET28a-D4MY01-NS5-22713 expression plasmid for 
DENV 4  FL NS5 mutants were transformed into BL21RIL E. coli cells 
(Stratagene, U.S.A.). 200 µl transformation reaction from each mutant 
was grown on Luria-Bertani (LB) agar plate containing 30 µg/ml 
Kanamycin (Kan) and incubated overnight (O/N) at 37 °C. Colonies 
were scraped and inoculated into two 500 ml LB broth + Kan and 
grown at 37 °C with shaking at 200 rpm until OD600 (optical density) 
was between 0.6-1.0. Protein expression was induced at 16 °C O/N 
with shaking at 200 rpm by the addition of 0.40 mM Isopropyl-β-D-
thiogalactopyranoside (IPTG; Invitrogen, U.S.A.) Cells were harvested 
by centrifuging at 6000 rpm for 10 min at 4 °C. The pellets were 




resuspended in 10 ml of cold nickel nitrilotricacetic acid (NiNTA) Buffer 
A (20 mM Tris-HCl pH 7.0, 500 mM NaCl, 5 mM β-mercaptoethanol, 5% 
glycerol) and stored at -20 °C until purification. 
 
2.2.2      Purification of DENV 4 FL NS5 mutant protein 
 Frozen cell pellets in NiNTA Buffer A were thawed on ice and 
supplemented with protease inhibitor cocktail Tablet (Roche, 
Switzerland) and 0.01% CHAPS (3-[(3-
cholamidopropyl)dimethylammonio]-1-propanesulfonate; Perbio, United 
Kingdom). Cells were lysed by sonication (Branson Digital Sonifier® 
homogenizers, U.S.A.) for 10 min at amplitude 40% with 5 sec pulse on 
and 10 sec pulse off. All purified proteins and lysate were kept on ice to 
prevent possible proteolysis or degradation. Cell debris was removed 
by centrifugation at 20 500 rpm for 45 min at 4 °C.  
 Clarified lysate was syringe-filtered before loading into His Trap 
High Performance Nickel 5 ml column (GE Healthcare, United Kingdom) 
pre-equilibrated with cold NiNTA Buffer A using AKTA fast protein 
liquid chromatographic System (GE Healthcare, United Kingdom). The 
His-tagged DENV 4 NS5 mutant proteins were eluted from column 
using gradient from 0 - 500 mM immidazole with 20 mM Tris-HCl, pH 
7.0, 550 mM NaCl, 5% glycerol and 5 mM β-ME (NiNTA Buffer B). 
Peak fractions were analyzed on 12% sodium dodecyl sulphate 
polyacrylamide gel electrophoresis (SDS-PAGE) gel stained with 
Instant blue (Expedeon, United Kingdom). The eluted fractions were 




pooled and proteins concentrated to 5 ml using Amicon Ultra tube 
(Millipore, U.S.A.) with molecular weight cut-off of 30 KDa.  
 Proteins were further purified with Superdex 200 gel filtration 
column (GE Healthcare, United Kingdom) using gel filtration buffer (20 
mM Tris-HCl, pH 7.0, 550 mM NaCl, 5% glycerol, 5 mM β-ME). Peak 
fractions were analyzed as previously stated. Fractions that showed a 
distinct 105 KD band from the SDS-PAGE gel, indicating presence of 
DENV 4 FL NS5 were concentrated using Amicon ultra tube and 
further quantified using NanoDrop1000 spectrophotometer (Thermo 
Fisher Scientific, U.S.A.) by measuring the absorbance of protein 
samples at 280 nm. Samples were aliquoted before snapped frozen in 
liquid nitrogen and stored at -80 °C. Expression and purification was 
previously done for WT DENV 4 NS5 by Seh Cheah Chen, NITD using 
the same method and was provided as a generous gift. 
 
 
2.3 In-vitro Transcription of pUC19-D4-5´UTR-L-3´UTR Plasmid  
 Plasmid containing the DENV 4 linked 5´UTR-3´UTR cloned 
downstream of T7 promoter was used as a template for PCR 
amplification of the 575 nt cDNA. PCR FOR and REV primers used 
corresponded to DENV 4 5´UTR followed by 3´UTR. Amplification was 
done using plasmid pUC19-D4-5´UTR-L-3´UTR (generous gift from Dr. 
Siew Pheng Lim, NITD) with primers D4-Bam-T7pro5´UTR-FOR and 
D4-10653-10632-3´UTR-REV respectively using MEGAscript kit 
(Applied Biosystem, U.S.A.) and following manufacturer´s protocol. 




PCR products were purified with Microspin G-25 column (GE 
Healthcare, United Kingdom). DNA was phenol:chloroform extracted 
and verified on 1.5% agarose gel electrophoresis. Its concentration 
was then determined using NanoDrop1000 by measuring absorbance 
at 260 nm.  
 In-vitro transcription (IVT) was then performed following the 
instructions on the MEGAscript T7 script protocol (Applied Biosystem, 
U.S.A.). A 20 µl reaction comprised 6 µg DNA template, 2 µl 10X 
Buffer, 2 µl each of 75 mM NTPs (rATP, rCTP, rGTP, rUTP), 2 µl T7 
RNA Polymerase. The setup was incubated at 37 °C for 6 hrs and 
digested with 1 µl 2U/µl DNase I for 20 min. Reaction mixture was 
purified using Microspin 2X G-25 column (GE Healthcare, United 
Kingdom) and phenol:chloroform extraction. Quality of RNA was 
verified by running on 1.5% agarose gel. Concentration was 
determined using NanoDrop1000 spectrophotometer by measuring 
absorbance at 260 nm. 
 
2.4 Cell-Free Assay 
 2.4.1 Biochemical Enzymatic Assays   
 Fluorescence-Based alkaline phosphatase–coupled polymerase 
assay (FAPA; Niyomrattanakit et al., 2010) is an enzymatic assay that 
was used to measure the RdRp de novo initiation and elongation 
activities of DENV 4 NS5 mutant enzyme proteins as compared to the  




WT. Assay was carried out in Corning Costar (Corning, U.S.A.) 96 well 
black opaque plates (half well plates) at room temperature (RT). The 
two buffers required for this assay were made for use within a week. 
Components of RdRP buffer varied with respect to assay type (FAPA 
de novo or elongation; described in detail in the next section). 
Reactions were ceased with 20 μl of freshly prepared 
deoxyethanolamine (DEA) or STOP buffer with 25 nM calf intestinal 
alkaline phosphatase (CIP) after 60 min or 120 min time point. Plates 
were further incubated for 60 min upon addition of STOP buffer with 
CIP.  
 All substrates were prepared prior to each experiment and 
diluted in the required buffer. BBT (ATTO) phosphate calibration 
solution (Jena, Germany) contained Atto substrate serially diluted 2X 
for up to 10 times providing a range of substrate concentrations from 
200 nM - 0.3906 nM. 30 µl of each dilution was transferred to wells 
accordingly and 20 µl CIP STOP buffer added. Each reaction was 
performed in triplicates and the experiments were repeated from 3 to 8 
times. Plates were read using Tecan Saffire II microplate reader 
(Tecan, Switzerland). BBT production through hydrolysis by CIP was 
determined at excitationmax and emissionmax wavelengths 422 nm and 
566 nm respectively. Results were expressed as the average 








2.4.1.1 FAPA De novo Initiation 
 The 30 µl reaction mixture contained 100 nM IVT 5´UTR-L-
3´UTR RNA, NTP mix [20 µM ATP, 20 µM GTP, 20 µM UTP, 5 µM 
ATTO-CTP (Trilink biotechnologies, U.S.A.), 100 nM of DENV 4 NS5 
mutant protein enzymes or WT. The required concentrations of 
substrates were obtained by diluting in RdRp de novo buffer. Buffer 
components and respective concentrations are shown in Table 2.2A. 
Assay was carried out by initially adding 20 µl of STOP buffer with CIP 
into 0 hr wells. 15 µl of enzyme was then added into respective wells. 
Plates were sealed with Microseal®B Adhesive sealer (Bio-Rad, 
Hercules, U.S.A.), shaken  for 30 sec, centrifuged at 1500 rpm for 1 
min and incubated RT for 20 min. 15 µl of IVT RNA + dNTP mix was 
then added to all wells. Plates were again shaken for 30 sec and 
centrifuged at 1500 rpm for 1 min and incubated RT for 120 min. 20 µl 
STOP buffer with CIP was then added to respective wells after 
incubation to stop reaction.  
 
 
2.4.1.2 FAPA Elongation Assay 
 The 30 µl reaction mixture contained 50 nM 3′UTR-U30 RNA 
(5´-bio-U30-AACAGGUUCUAGAACCUGUU-3´ purchased from 
Dharmacon, U.S.A.) and 2 nM ATTO-ATP (Promega, U.S.A.), 20 nM 
DENV 4 NS5 mutant protein enzymes and WT. The required 
concentrations of substrates were obtained by diluting in RdRp 




elongation buffer. Buffer components and respective concentrations 
are shown in Table 2.2B.  
 Assay was carried out by initially adding 20 µl of STOP buffer 
with CIP into 0 hr wells. 5 µl 1X RdRp elongation buffer and 5 µl of 
RNA primer template 3′UTR - U30 RNA (5´-bio-U30-
AACAGGUUCUAGAACCUGUU--3´) (Niyomrattanakit et al., 2010) was 
then added to all wells followed by the addition of 10 µl of enzyme into 
respective wells. Plates were sealed with Microseal®B Adhesive sealer 
(Bio-Rad, Hercules, U.S.A.), shaken for 30 sec, centrifuged at 1500 
rpm for 1 min and incubated RT for 30 min. This was to allow the 
enzyme to bind to the promoter region on the 3´UTR-U30 RNA 
template. 10 µl ATTO-ATP was then added to all wells. Plates were 
again shaken and spun as previously stated and then incubated at RT 
for 120 min. 20 µl STOP buffer with CIP was added to respective wells 















Table 2.2: Summary of Standard Assay Condition for FAPA De 
novo Initiation and Elongation 










Total volume (µl) 30 20 50 
Tris-Cl pH 7 50 mM - 30 mM 
NaCl - 200 mM 80 mM 
MnCl2 0.3 mM - 0.6 mM 




      - 
0.006% 
(v/v) 
KCl 10 mM       - 6 mM 
Cysteine 10 µM       - 6 µM 
DEA pH 10 - 1.5 M 0.6 M 
CIP - 25 nM 10 nM 
Enzyme (DENV 4 NS5 WT 
and mutants) 100 nM 
- 
12 nM 
IVT- RNA template 100 nM - 30 nM 
NTPs (ATP, GTP, UTP) 20 µM -  12 µM 
ATTO-CTP  5 µM - 1.2 µM 
 










Total volume (µl) 30 20 50 
Tris-Cl pH 7 50 mM - 30 mM 
NaCl - 200 mM 80 mM 
MnCl2 1 mM - 0.6 mM 
MgCl2 - 25 mM 10 mM 
Triton-X-100 (Trx-100) 0.01% (v/v)       - 0.006% (v/v) 
DEA pH 10 - 1.5 M 0.6 M 
CIP - 25 nM 10 nM 
Enzyme (DENV 4 NS5 




template 50 nM 
- 
30 nM 
ATTO-ATP  2 µM - 1.2 µM 
 




2.4.2 Differential Scanning Fluorimetry (Thermofluorescence 
Assay) 
 The thermofluor experiment was used to determine the Melting 
temperatures (Tm) of mutant proteins as compared to WT. A total of 20 
µl reaction mixture comprised 2.5 μM freshly thawed DENV 4 FL NS5 
protein, 62.5X freshly diluted SYPROorange Dye (Invitrogen, 
Singapore) and 1X assay buffer (50 mM Tris pH 7.5, 100 mM KCl, 
0.001% Triton X 100, 0.1 mM MnCl2, 0.1 mM MgCl2). The reaction set 
up was done in triplicates in a 96-well PCR white opaque plate (Bio-
Rad, Hercules, U.S.A.). The plate was sealed with Microseal®B 
Adhesive sealer (Bio-Rad, Hercules, U.S.A.) and spun at 1500 rpm for 
1 min.  
Thermodenaturation was performed by heating the samples 
from 25 °C to 85 °C with increments of 0.5 °C, using iQ™5 Multicolor 
Real-Time PCR Detection System (Bio-Rad Hercules, U.S.A.). 
Fluorescence was detected at excitationmax 485 nm and emissionmax 
625 nm. Signals were recorded as change in relative fluorescence unit 
(RFU) with respect to temperature and their derivatives (-dRFU/dT) 
were plotted using GraphPad Prism version 5 (GraphPad Software, 
U.S.A.). 
 
2.4.3 Measurement of Steady-state Kinetic Parameters 
 The steady-state kinetic parameters of DENV 4 FL NS5 protein 
samples were used to determine the Michaelis-Menten constant (Km), 
kcat and Vmax of the substrates RNA and NTP. De novo FAPA assay 




was employed and experiments were carried out by varying 
concentrations of one substrate in the presence of the second 
substrate kept in excess at a constant concentration. For the negative 
control, STOP buffer was added prior to the other reactants. 
Experiments were repeated for up to five times and each reaction 
performed in duplicates. Km, kcat and Vmax results were obtained using 
GraphPad Prism version 5 software. 
 
 
2.4.3.1 RNA Km Studies in De novo Assay 
  IVT RNA was serially diluted two fold for up to 10 times 
providing a range of substrate concentrations from 250 nM - 0.488 nM. 
The NTP concentration was fixed at 10 µM of each nucleotide 
(saturating condition). 10 µl of the different serially diluted RNA were 
dispensed into their respective wells. 10 µl of 10 µM NTP mix was 
added into all wells. Plates were sealed with Microseal®B Adhesive 
sealer (Bio-Rad, Hercules, U.S.A.), shaken  for 30 sec and centrifuged 
at 1500 rpm for 1 min. 10 µl of 100 nM of WT DENV 4 FL NS5 and 
mutant samples were then dispensed into respective wells. Plates were 
again shaken for 30 sec and centrifuged at 1500 rpm for 1 min. After 2 
hr incubation at RT, STOP buffer was added. 
 
 




2.4.3.2 NTP Km Studies in De novo Assay 
 NTP substrates were serially diluted 10 times in order to provide 
concentrations ranging from 30 µM - 0.5 µM. 10 µl of 250 nM RNA was 
added to all wells followed by the addition of 10 µl of 100 nM WT DENV 
4 FL NS5 and mutant samples into respective wells. Plates were 
sealed with Microseal®B Adhesive sealer (Bio-Rad, Hercules, U.S.A.), 
shaken for 30 sec, centrifuged at 1500 rpm for 1 min and then 
incubated. After 2 hr incubation at RT, CIP in STOP buffer was added. 
 
 
2.5 Cloning of DENV 2 TSV01-F subclone mutants  
 Alanine mutants of FL DENV 2 TSV01 were made for viral 
infection studies in comparison to the WT infectious clone. To make 
construct of the various mutations in DENV 2 FL NS5 (F399A, N493A, 
Y607A, N610A, D664A and W796A), template plasmid TSV01-F 
subclone containing DENV 2 TSV01 NS4B-NS5cDNA-3´UThv R + 
HDVr (Hepatitis D virus ribozyme) - a gift from Zou et al., (2011), was 
used to perform SDM using instructions and kit from Quik Change II XL 
SDM kit (Stratagene, U.S.A.). Components of the reaction mixture and 
cycling conditions are as previously stated for the DENV 4 FL alanine 
mutants. Primers for TSV01-F subclone mutants (AITbiotech, 
Singapore) are shown in Table 2.3.  
 
 




Table 2.3: DENV 2 Mutant Primers for Site-specific Mutation in 





























































Nomenclature for primers are described as Dengue virus serotype 2 (D2), non-
structural protein (NS5), the alphabets preceding each numbers are the standard 
single amino acids nomenclature for each amino acid residue that was mutated to 
alanine (A). For instance W796A indicates tryptophan amino acid at position 796 was 
mutated to alanine. FOR and REV represents the "forward" and "reverse" primers 
respectively The primer sequence has been designated with the standard three 




QIAquick PCR purification kit (QIAGEN, U.S.A.) was used to 
purifiy the mutated plasmids before transformation into XL1-Blue 
supercompetent cells (Stratagene, U.S.A.). 200 µl of each 
transformation reaction were grown on LB agar plate containing 100 
µg/ml  Ampicillin (Amp) and incubated O/N at 37 °C. Colonies from 




plates were inocculated into  4 ml LB broth + Amp and grown O/N at 
37 °C with shaking at 220 rpm. Plasmid DNA was isolated and purified 
using QIAprep Spin Miniprep Kit (QIAGEN, U.S.A.). Mutations to Ala as 
well as NruI and ClaI restriction sites were verified by DNA sequencing 
(1st BASE Sequencing, Singapore). 
 
 
Table 2.4: DENV 2 Primer for Site-specific Mutation in TSV01-F 
   Subclone Plasmid by Overlapping PCR 
ID 
number Primers Sequence 
1 TSV01-NruI-FOR 51-CTGTGTCGCGAGGCTCG-31 
2 TSV01-ClaI-REV 51- CTTGCCATCGATAGACATG-31 
 
Nomenclature for Dengue 2 TSV01 subclone PCR primers are described based on 
the NruI and ClaI restriction digestion sites. FOR and REV represents the "forward" 
and "reverse" primers respectively. The primer sequence has been designated with 




2.6 Cloning of DENV 2 TSV01-F Subclone K402A Mutant using 
 Overlapping PCR  
 Point mutation from lysine (K) to alanine (A) in DENV 2 TSV01-F 
subclone position 402 on the NS5 region was made by overlap 
extension PCR. Primers for TSV01-F subclone mutant K402A (Table 
2.4) in addition to the forward (FOR) and reverse (REV) primers 
incorporating NruI and ClaI restriction sites (Table 2.4) respectively 
were designed and ordered (AITbiotech, Singapore). The plasmid 
template TSV01-F subclone containing DENV 2 TSV01 NS4B-NS5 




cDNA-3´UThvR+HDVr (Hepatitis D virus ribozyme) was used as PCR 
amplification target for NS5 region of interest.  
 A 50 µl PCR 1 and PCR 2 reaction mixture comprised 1 µl of 20 
ng/µl DNA template, 5 µl of 10x reaction buffer, 1.25 µl of 10 µM 
FOR/REV Primers, 1 µl of 10 mM dNTPs, 1 µl of 2.5 U/µl PFU DNA 
polymerase enzyme (Stratagene, U.S.A.). Primer template pair TSV01-
NruI-FOR and D2 NS5-K402A-REV were used for PCR 1 with cycling 
conditions - initial denaturation: 95 °C for 3 min; 30 cycles of 
denaturation: 95 °C for 1 min; annealing: 55 °C for 1 min; extension: 
68 °C for 1.5 min and final elongation: 68 °C for 2 min. Primer template 
pair TSV01-ClaI-REV and D2 NS5-K402A-FOR were also used for 
PCR 2 with cycling conditions - denaturation: 95 °C for 3 min; 30 cycles 
of denaturation: 95 °C for 1 min; annealing: 55 °C for 1 min; extension: 
68 °C for 2.5 min and final elongation at 68 °C for 3 min.  
 PCR 1 and 2 products were used as templates to make the 
DENV 2 TSV01-F subclone K402A gene (PCR 3). A 50 µl reaction 
mixture comprised 10 µl of 5X Phusion HF Buffer, 2.5 µl of 10 µM NruI-
FOR/ClaI-REV Primers, 1 µl of 10 mM dNTPs, 0.5 µl Phusion DNA 
Polymerase (Finnzymes, Finland), 1.8 µl of 49 ng/µl PCR 1 and 8 µl of 
11 ng/µl PCR 2 DNA templates, with cycling conditions - initial 
denaturation: 98 °C for 30 sec, 35 cycles of denaturation: 98 °C for 10 
sec; annealing: 58 °C for 30 sec; extension: 72 °C for 51 sec and final 
elongation at 72 °C for 5 min. All PCR products were verified on 1.2% 
agarose gel. Mutation to Ala as well as NruI and ClaI restriction sites 
were verified by DNA sequencing (1st BASE Sequencing, Singapore). 




2.7 Construction of Recombinant Plasmids 
 The DENV 2 pACYC-FL TSV01-F vector containing the 
infectious FL DENV 2 cDNA (gift from Zou et al., 2011) and DENV 2 
TSV01-F subclone mutants were digested with NruI at 37 °C for 2.5 hr. 
The 50 μl reaction mix comprised of 5 μl 10X NEBuffer 3, 1.5 μl of NruI 
(10 U/ μl) (NEB, U.S.A.) and 0.5 - 1 μg of vector and mutant samples. 
The digested products were passed through QIAquick PCR purification 
kit (QIAGEN, U.S.A.). NruI digested and purified products were further 
incubated with ClaI at 37 °C for 2.5 hr. The 50 μl reaction mix 
comprised of 5 μl 10X NEBuffer 4, 5 μl 10X BSA and 1.5 μl ClaI (10 U/ 
μl) (NEB, U.S.A.). 1 μl CIP (NEB, U.S.A.) was further added to the 
reaction setup of NruI digested pACYC-FL TSV01 plasmid.  
 NruI and ClaI digested products were verified and separated on 
0.8% agarose gel. 11kb band from pACYC-FL TSV01 plasmid and 
3.1Kb insert from TSV01-F subclones mutations (F399A, N493A, 
Y607A, N610A, D664A and W796A) were excised. DNA samples were 
extracted and purified using QIAquick gel extraction kit (QIAGEN, 
U.S.A.) and quantified using NanoDrop1000 by measuring the 
absorbance at 260 nm. The 3.1 kb NruI and ClaI digested DENV 2 
TSV01-F subclone K402A (PCR 3) was passed through QIAquick PCR 
purification kit (QIAGEN U.S.A.) after the NruI/ClaI and concentrations 
determined by measuring the absorbance of DNA at 260 nm. 
 
 




2.8 Ligation of DENV 2 pACYC-FL TSV01 with TSV01-F 
Subclone Mutants 
 Recombinant plasmids were constructed using NS5 region of 
TSV01-F subclone mutants containing the mutation of interest and 
pACYC-FL TSV01 plasmid (bearing infectious cDNA clone of WT 
DENV-2 pACYC TSV FL; strain TSV01). The 15 μl ligation reaction 
comprised of 1.5 μl ligase Buffer (X10), 1 μl NEB T4 DNA ligase with 
10 mM ATP. The ligation kit was supplied by NEB, U.S.A. 11 kb 
NruI/ClaI digested pACYC-FL TSV01 plasmid and 3.1 kb NruI/ClaI 
digested TSV01-F subclone mutants (inserts). The total amount of 
DNA in the ligation reaction was between 300 - 500 ng/μl with ratio of 
plasmid to insert being 1:3. The reaction setups were Incubated O/N at 
16 °C. Ligated DNA was purified using phenol:chloroform method 
followed by ethanol precipitation. Purified DNA constructs were 
transformed into TOP10 chemically competent cells (Invitrogen, 
Switzerland). 200 μl of each transformation reaction were grown on LB-
agar plate + Amp (100 μg/ml) after recovery at 37 °C for 1 hr using 
commercially made S. O. C media (Invitrogen, Switzerland). Plates 
were incubated O/N at 30 °C. Colonies from plates were inoculated into  
5 ml LB broth + Amp (100 μg/ml) and grown O/N at 37 °C with shaking 
at 220 rpm.  
 Plasmid DNA were isolated and purified using QIAprep Spin 
Miniprep Kit (QIAGEN, Singapore). OD260 NanoDrop1000 of the ligated 
DNA constructs were obtained. Samples were further digested with  




XbaI and ClaI restriction enzymes. The 20 μl double digestion reaction 
mix comprised of 2 μl 10X BSA, 2 μl 10X NEBuffer 4, 1 μl of ClaI 
(10U/μl), 1 μl of XbaI (10U/μl) and 400 ng of ligated plasmid DNA 
mutants using pACYC-FL TSV01 plasmid as control. ClaI/XbaI 
digested products were verified on 0.8% agarose gel. 14.4 kb Positive 
clones produced 4.9 kb and 9.5 kb bands upon digestion.  
 To further confirm that the clones were positive, PCR was 
carried out. A 50 µl reaction mixture comprised 1 µl of 15 - 50 ng/µl 
DNA mutant plasmid template, 5 µl of 10x PFU buffer, 1 µl of 10 µM 
FOR/REV Primers, 1 µl of 10 mM dNTPs, 1 µl of 2.5 U/µl PFU DNA 
Polymerase. Cycling conditions were - initial denaturation: 95 °C  for 3 
min; 30 cycles of denaturation:95 °C for 1 min; annealing: 55 °C for 1 
min; extension: 68 °C for 15 min and final elongation at 68 °C for 15 
min. pACYC-FL TSV01 plasmid was used as a positive control. The 
forward and reverse primers used were TSV01-9583V and TSV01-
10723C primers (Table 2.5). PCR products were run on 0.8% agarose 
gel. Positive clones produced 1 kb. DNA sequencing was done to 
determine the presence of desired insert, 5´UTR-3´UTR ends were 











Table 2.5: DENV 2 TSV01 Primers used for PCR 
ID 
number Primers Sequence 







Nomenclature for Dengue 2 TSV01 subclone PCR primers are described based on 
the nucleotide position (9583 and 10723) in the forward (V) and reverse (C) order. 
The primer sequence has been designated with the standard three codon from their 




2.9 Production of Recombinant Viruses 
2.9.1 Linearization of Plasmid 
 Alanine mutants of FL DENV 2 pACYC TSV01 were made for 
viral infection studies in addition to the WT infectious clone. The 
reaction was prepared in triplicate. Each 50 μl reaction mix comprised 
5 μl 10X NEBuffer 4, 5 μl 10X BSA, 3 μl ClaI (10 U/μl), 4 μg pACYC-FL 
TSV01 WT plasmid and mutants. The setup was incubated with at 37 
°C for 2 hrs. Linearized DNA plasmids were pooled, phenol:chloroform 
extracted followed by ethanol precipitation. The samples were 
incubated at −80 °C O/N and spin at 14 rpm, 4 °C for 30 min to pellet 
the DNA. Linearized samples were verified on 0.8% agarose gel and a 
1:5 dilution was used to measure the OD260 nanodrop 1000. 
 




2.9.2 In-vitro Transcription of DENV 2 FL pACYC-FL TSV01  
 In-vitro transcription (IVT) was performed using T7 mMESSAGE 
mMACHINE kit (Ambion, U.S.A.). The 20 μl reaction mix for pACYC-FL 
TSV01 WT plasmid and mutants comprised of 2 μl 10X Buffer, 10 μl 2X 
NTP mix, 0.75 μl GTP (30 mM), 1.5 μg linearized DNA template and 2 
μl T7 RNA enzyme mix. The set up was incubated for 4 hrs at 37 °C, 
followed by 1 ul of 15 min Dnase treatment at 37 °C.  
 RNA was precipitated by adding 30 μl nuclease free water, 3 μl 
glycogen and 30 μl of LiCl precipitation solution, mixed and chilled O/N 
at -20 °C. It was next centrifuged at 4 °C for 30 min at 14 rpm to pellet 
the RNA. Pellets were further washed with 70% ethanol, air dry and 
dissolved in 10 μl RNAse free water. The expected single band of 11 
kb IVT RNA was verified on 0.8% agarose gel. A 1:5 dilution was used 
to measure the OD260 nanodrop 1000. RNA samples were aliquoted in 
tubes with 8 μg and frozen. 
 
2.10 Cell Culture and Cell Lines 
 Cell media and culture preparations were done under aseptic 
environment in a class two type A2 biohazard safety cabinet (Gelman 
Sciences, Singapore). All cell culture incubations were performed in 
37 °C, 5% CO2 humidified incubator. Two different types of baby 
hamster kidney fibroblast (BHK)-21 cell lines were used in this study.  




 The (BHK)-21 (US) cell line (gift from Xuping Xie, NITD) was 
used for indirect immunofluorescence assay (IFA) and only cells 
between the passage numbers of 5 and 10 were used. The BHK -21 
(NITD) cell lines (gift from Ghafar Nahdiyah, NITD) was used for 
plaque assay to determine viral titre and cells between passage 
numbers of 15 and 20 were used in this assay. The cells were grown 
and maintained in sterile corning T75 and T175 cm2 plastic tissue cell 
culture flasks with 2 μM vent cap and angled neck (Corning 
incorporated, U.S.A.). 
 
2.11 Media for Cell Biological Studies 
 Dulbecco´s modified eagle´s media (DMEM) high glucose 
(Invitrogen, U.S.A.) was used as growth medium to culture BHK-21 
(US) cells. Roswell park memorial institute (RPMI) -1640 media (Sigma, 
U.S.A.) was used to culture BHK-21 (NITD) cells. Both media 
preparations used for passaging of cell lines were done according to 
manufacturer´s specifications. DMEM was supplemented with 10% 
fetal bovine serum (FBS), 2% glutamine and 1% penicillin/streptomycin 
antibiotics. RPMI media was supplemented with 10% FBS (R10) and 1% 
penicillin/streptomycin. Both media were filter-sterilized before used. 
Freezing media used for cell storage was made up of 95% FBS and 5% 
DMSO. 
  During IFA, DMEM without 1% penicillin/streptomycin were used 
in maintaining electroporated cells for 24 hr post transfection. DMEM 




media was then, aspirated and replaced with complete DMEM media 
for the next 72 hrs of incubation. RPMI media with 2% FBS (R2) and 1% 
penicillin/streptomycin were used for viral serial dilution and incubation 
of infected BHK-21 (NITD) cells.  
 Overlay media was used for plaque assay. It consists of 0.8% 
methyl cellulose, 1x RPMI, 0.5% dimethyl sulfoxide (DMSO), 0.05% 
Na2CO3, 0.025M HEPES buffer, 2% FBS and 1% 
penicillin/streptomycin. The overlay media was dispensed onto infected 
BHK-21 (NITD) cells to prevent secondary infection by virus produced 
from neighboring cells.  
 
 
2.12 Growing and Maintaining of Cell Lines 
 Cells frozen in freezing media in 1.5 ml cryo-vials were stored in 
-80 °C. To grow and maintain cells, vial were retrieved and thawed in a 
37 °C water bath. Thawed cells were immediately transferred into a 50 
ml falcon tube containing 10 ml of pre-warmed desired cell growth 
media and centrifuged at 1200 rpm for 3 min. The growth medium was 
needed to dilute the toxic effects of DMSO. The supernatant was 
discarded and pelleted cells were resuspended in 12 ml of complete 
media.  
 The cell suspension was pippeted up and down several times to 
eliminate cell aggregates and then transferred into a T75 cm2 flask and  




incubated at 37 °C with 5% CO2. Cell cultures were periodically 
examined under the microscope to check confluency and also to 
confirm the absence of bacteria and fungi contaminants. Cells were 
allowed to grow to confluence for about 2-3 days before sub-culturing.  
 When cells were confluent, the medium was discarded and the 
cell monolayer was washed with 10 ml PBS to remove serum. Cells 
were incubated with 1 ml of trypsin for 2 min at 37 °C and observed 
under microscope to ensure that they were detached from the cell 
monolayer. The sides of the flask were tapped gently to dislodge 
adherent cells. 9 ml of growth medium was immediately added to 
inactivate the enzymatic effect of trypsin. Contents were transferred 
into a 50 ml falcon tube and centrifuged at 1200 rpm for 3 min.  
 The supernatant was discarded and pelleted cells were 
resuspended in 10 ml of complete media. Cell suspension was 
pippeted up and down several times to eliminate cell aggregates. The 
suspension of cells was split into a seeding ratio of 1:4 in T175 cm2 
flask for IFA or plaque assay or a seeding ratio of 1:8 for maintaining 
the cell lines into a T75 cm2 flask and topped up with complete growth 
medium to either 20 ml or 10 ml respectively for incubation. Cells 
seeded in ratio 1:4 reached confluence in about 24 hrs and are then 








2.13 RNA Transfection of Cells 
 Gene pulser cuvette (0.4 cm) (Bio-Rad, China) was chilled on 
ice. T 175 cm2 flasks were observed under microscope to ensure BHK-
21 (US) cells were confluent and healthy. Cells were trypinsized as 
previously indicated. Trypinsized cells from each flask were combined 
into a 50 ml falcon tube and centrifuged at 415 g for 5 min. Cell media 
was aspirated and pellet was suspend in 30 ml of cold PBS, mixed and 
centrifuged at 415 g for 5 min. C-chip disposal hemocytometer (Digital 
Bio, Korea) was used to count cells. Cells were counted by taking 20 µl 
from the 30 ml cell suspension and 20 µl of 0.4% trypan blue solution 
(Sigma, U.S.A.) added.  
 PBS was aspirated and pellet re-suspended an appropriate 
volume of cold PBS to make total cell number 1x107. 8 μg of RNA from 
each sample was placed in the cuvette in addition to 800 μl of the re-
suspended cell (8x106 cells). Contents were mixed by pipetting up and 
down and the pulsed 3 times using genepulser (Bio-Rad, U.S.A.) with 
5-10 sec interval at condition: Voltage=850, µF=25, resistance=∞, 
cuvette=0.4 cm. Cells were allowed to recover at RT for 10 min. After 
recovery, contents of the cuvette were transferred into falcon tube 
containing 7.2 ml of DMEM media with no antibiotics. The final cell 
number was 1x106 per ml.  
 Sterilized coverslips for immunofluorescence microscopy were 
placed in labeled wells of four 24 well plate (Nunclon, Denmark). 50 μl 
of cell suspension from falcon tube was introduced into each well and 
topped up with 450 μl of DMEM media with no antibiotics. Final cell 




number in each well was 1x105. Remaining cells in the falcon tube 
were transferred into a T175 flask and topped up to 25 ml DMEM 
media with no antibiotics. Plates and flask containing electroporated 
cells were incubated at 37 °C for day 1 time point and then at 30 °C 
with 5% CO2 for day 2 to 4 time point. 
 After 24 hr, DMEM media with no antibiotics from the flask was 
aspirated and filled with complete DMEM media. During the day 1 to 4 
incubation periods, 3 ml of culture fluid from the flasks were harvested, 
centrifuged at 2000 rpm for 3 min to pellet cell debris and the culture 
media from viral RNA electroporated cells aliquoted, and stored at 
−80 °C. 
 
2.14 Cell-Based Assay 
2.14.1 Indirect Immunofluorescence Assay  
 Transfected cells were washed ~5 times with PBS, and fixed in 
100% cold methanol (Sigma Aldrich, U.S.A.) after media aspiration. 
Plates were incubated at -20 °C for at least 20 min. Plates were again 
washed once with PBS and cells blocked with PBST (composed of 1% 
FBS, 1% BSA and 0.05% Tween-20) at RT for 1 hr to prevent non-
specific binding of antibodies. To detect expression of viral envelope, 
NS5 protein and double-stranded (ds) viral RNA; 30 μl of the diluted 
primary antibody (Table 2.6) was spotted on parafilm. Coverslips fixed 




with cells were then inverted over the drop of primary antibody and 
incubated at RT for 1 hr.  
Table 2.6: Primary Antibodies and their Working Dilutions 
Coverslip Primary Antibody Dilution 
1 
 anti-mouse 4G2  




(Genetex, U.S.A.)    1:500        
anti-mouse-dsRNA 
(Genetex, U.S.A.)  1:100 
 
 
Coverslips containing cells were then washed ~5 times with 
PBST. 30 μl of diluted secondary antibody (Table 2.7) was again 
spotted on fresh parafilm. Coverslips previously stained with primary 
antibody were then inverted over the drop of antibody and incubated in 
dark at RT for 45 min.  
Table 2.7: Secondary Antibodies and their Working Dilutions 
Coverslip Secondary Antibody Dilution 
1 
α-mouse-FITC-labeled goat 
anti-mouse IgG (Sigma, 
U.S.A.) 1:100 
2 
2 mg/ml Alexa Fluor 594 
goat anti-rabbit IgG 
(Invitrogen, U.S.A.) 1:2000 
α-mouse-FITC-labeled goat 








Coverslips were then washed ~5 times with PBST and mounted 
on glass slide containing 5ul X2 4´,6-diamidino-2-phenylindole (DAPI) 
(Vector laboratories, U.S.A.). Fluorescence was visualized under laser-
scanning optical immunofluorescence with a 63x oil-immersion 
objective (Leica DM 4000B, United Kingdom). The same procedures 




2.14.2  Plaque Assay 
 Viral titers of culture media collected from BHK-21 (US) cells at 
day 4 post-transfection were quantified through a single layer plaque 
assay. BHK-21 (NITD) cells (2 X 105) were seeded per well in a 24-well 
plates and left at RT for ~20 min to allow cells to spread out uniformly. 
Cells were then incubated for 24 hr at 37 °C with 5% CO2 to reach 
confluence. A series of 1:10 dilutions was made by mixing 100 μl of cell 
supernatant from viral RNA electroporated cells with 900 μl of RPMI 
media containing 2 % FBS and 1% penicillin/streptomycin antibiotics 
from 10-1-10-9 dilutions.  
 RPMI complete media was aspirated from the seeded cells and 
aliquots containing 100 μl of appropriate dilutions were inoculated onto 
respective wells containing cell monolayer. The virus was allowed to 
infect the cells at 30 °C with 5% CO2 for 1 hr. The virus media was then 
aspirated and 600 μl of 0.8% methyl-cellulose RPMI overlay media 




(Calbiochem, U.S.A.) containing 2% FBS was dispensed to each well 
to prevent the viral infection from spreading indiscriminately.  
 Plates were then incubated for 4 days at 37 °C with 5% CO2. 
After the incubation period, cells were fixed in 3.7% formaldehyde 
(Sigma, U.S.A.) for 45 min. The overlay media was decanted and 
plates were stained with 1% crystal violet solution and dried in 50 °C 
oven. The plaque number was determined by visual inspection of 















3.1 Site-directed Mutagenesis 
  All nine mutant clones (F399A, K402A, F486A, N493A, G605A, 
Y607A, N610A, D664A and W796A) of DENV 4 FL NS5 were 
successfully generated by SDM through the introduction of point 
mutations (to Ala) into template plasmid pET28a-D4MY01-NS5-22713. 
Addition of DpnI after temperature cycling was used to digest 
methylated and hemimethylated parental DNA template and to select 
for nicked mutant plasmid containing synthesized DNA (Nelson and 
McClelland, 1992). The nicked vector DNA containing the desired 




3.2 Expression and Purification of DENV 4 FL NS5 Mutant 
Proteins 
               DENV 4 FL NS5 were expressed and purified successfully in 
E. coli. Addition of IPTG to the transformed cells inactivated the lac 
repressor protein and induced lac operon gene allowing protein 
expression to occur (Bell and Lewis, 2000). The growth of bacteria 
culture were checked periodically during the incubation period until it 
reached a range of OD600 within 0.6 - 1.0 for pre induction and 1.5 - 1.9 
for post induction. Samples were collected to check for protein 




expression during the pre and post-IPTG induction before harvesting 
(Figure 3.1).  
              The mutant proteins contained N-terminal-His-tag which 
promoted affinity binding to the Ni+ ions in the His Trap Nickel column 
resin (affinity chromatography). 500 mM NaCl and 5 mM β-
mercaptoethanol were included in the buffers to reduce nonspecific 
protein binding (Bornhorst and Falke, 2000). The presence of 500 mM 
Imidazole in buffer B (elution buffer) competed with the His-tagged 
protein samples bound to the nickel column resulting in the elution of 
the bound proteins. All samples purified through nickel columns yielded 
similar elution profiles (Figure 3.2 A). Aliquots of fractions were 
analyzed with 12% SDS-PAGE to check the molecular weights of the 
proteins (Figure 3.2 C). Fractions corresponding to bands F1 are flow 
through samples containing denatured and cell protein debris. The 105 
kD band in F2 contained purified his-tagged NS5 protein of interest 
whilst the unwanted bands around 30 kD indicated truncated NS5.  
             As previously discussed, the His-tagged FL NS5 containing 
RdRp and MTase domain was finally purified from truncated MTase 
proteins at different rates based on their sizes using Superdex 200 gel 
filtration column (size exclusion chromatography). From the gel 
filtration chromatogram in Figure 3.2 B, NS5 having a higher molecular 
weight of 105 kD eluted first (F5) before 30 kD molecular weight of 
MTase (F6). Aliquots of gel filtration purified fractions were again 
analyzed with 12% SDS-PAGE which separated the two proteins 
according to their electrophoretic mobility. Bands from F4 showed 




minimal concentrations of NS5 indicating commencement of separation 
and elution of NS5 from MTase in the gel filtration column. Higher 
concentrations of NS5 (shown by the thick bands of F5) were then 
eluted as the purification process progressed. Fractions containing 
DENV 4 FL NS5 mutant proteins of distinct 105 kD band which as well 
corresponded to peak on the graph (Figure 3.2 B; Figure 3.2 C) were 
selected for concentrating to about 250 μl. Other protein fraction 
corresponding to 30 kD bands or indicating traces or mixtures of NS5 
with the MTase were discarded.  
 
Figure 3.1: Protein expression and purification profile of DENV 4 FL NS5  
Lane 1: protein standards (NEB, U.S.A.). Lane 2: after pre-induction of cell culture during 
protein expression Lane 3:after post induction of protein expression Lane 4: post 
sonication Lane 5: clarified supernatant after centrifugation and before passing through 
His-trap nickle column Lane 6: protein sample after passing through His-trap nickle 




              All FL mutant proteins showed similar mobility on 12% SDS-
PAGE gel as to WT FL NS5 protein (Figure 3.2 B and Figure 3.3). 
Protein yield of between 0.19 - 17.00 mg per liter of expression culture 
were obtained after purification of DENV 4 FL NS5 mutants (Table 3.1). 
Mutants F399A and F486A presented the lowest yield during the 
purification process. 





Figure 3.2: Purification profile of DENV 4 FL NS5  
Using purification of Y607A as an example; A) Indicates a typical elution profile from the His-
trap nickle column during purification of his-tagged mutant proteins. Aliquots of fractions 1, 2 
and 3 (F1, F2 and F3) were used for 12% SDS-page gel analysis. B) Shown here is a typical 
elution profile for superdex 200 gel filtration chromatography. Aliquots of peak fractions 4, 5 
and 6 (F4, F5 and F6) were used for 12% SDS-page gel analysis. C) Results from12% SDS-
page gel with fractions from His-trap nickel and superdex 200 gel filtration column. Aliquots 








   
Figure 3.3: Purified proteins of DENV 4 FL NS5  
12%SDS-PAGE gel showing ~105 kD bands with 8 uM each of DENV 4 FL NS5 
mutants and WT proteins.  
 
Table 3.1: DENV 4  FL NS5 Mutant Protein Yield 














3.3 In-vitro Transcription of RNA using DENV 4 Template 
 DENV subgenomic RNA (in-vitro transcribed RNA) was used as 
template for FAPA de novo initiation assay and to determine the 
steady-state kinetic parameters of RNA and NTP substrates. Expected 
single band of 600 nt cDNA and 575 nt IVT RNA (Figure 3.4) was 
verified on 1.5% agarose gel electrophoresis. 





FIgure 3.4: In-vitro transcription of plasmid pUC19-D4-5'UTR-L-3'UTR 
Lane 1 in (A) and (B) contains 100 bp DNA ladder (NEB, U.S.A.). A) Lane 2 indicates 600 
nt of PCR product from DENV 4 cDNA.  Lane 3 corresponds to control 600 nt cDNA  B) 
Lane 2 indicates 575 nt band of IVT RNA generated from MEGAscript kit. Lane 3 
corresponds to control 575 nt RNA 
 
 
3.4 Background of Biochemical Enzymatic Assays 
 The FAPA endpoint enzymatic assay was used to examine the 
biological importance of the amino acid residues at the catalytic side of 
RdRp upon mutation to Ala in DENV 4 FL NS5 during de novo initiation 
and elongation phase. This was to determine the effects of mutations in 
RdRp activity during RNA replication as compared to WT DENV 4 FL 
NS5. Dengue virus serotype 4 was chosen for the cell free assay due 
to its stability (Zou et al., 2011).  
 The attachment of benzene ring in BBT to the phosphate group 
in ATP resulted in the simultaneous release of BBT-PPi during the 
incorporation of nucleotides to the viral RNA template (Figure 3.5). 
DAE in the STOP buffer provided the buffer components required for 
the CIP enzyme to catalyze the irreversible breakdown of BBT-PPi 
which produced an inorganic phosphate (Pi) and the alcohol, 2´-[2-
benzothiazoyl]-6´-hydroxybenzothiazole (BBT), [BBT+PPi]. This 




enables free BBT to fluoresce and be detected at excitationmax and 
emissionmax wavelengths 422 nm and 566 nm respectively. Thus, 
higher in enzymatic activity results in an increase in number of ATP 
nucleotides incorporated to the RNA which subsequently increases the 
amount of BBT released resulting in the higher measurement of higher 
fluorescence (average RFU).  
 
 
Figure 3.5: Schematic diagram showing principle for measuring NS5 RdRp  
activity (Niyomrattanakit et al., 2010)  
The simultaneous release of BBT-PPi during incorporation of ATP in the form of  
BBT-ATP (Atto-ATP) onto RNA template by RdRp. This results in the subsequent  
removal of BBT from PPi by CIP causing BBT to fluoresce at excitationmax and  




 The addition of cysteine in the de novo buffer was used to 
prevent the formation of disulfide bonds between thiol groups of 
cysteine residues in the RdRp enzyme thereby preventing the 
formation of protein aggregation. Addition of MnCl2 and MgCl2 diavalent 
cation enhanced enzyme activity in the RdRp buffer whilst higher 
concentrations of NaCl in the stop buffer inhibited the RdRp enzyme.  




 The enzymatic activities of DENV 4 FL NS5 mutant proteins 
were classified into four categories as indicated below (Table 3.2). The 
results acquired for the nine FL mutant proteins were compared to WT 
FL NS5 (100% activity), to obtain the average percentage activity of 
each protein. The classification in Table 3.2 would be referred during 




3.4.1 FAPA De novo Initiation 
 This assay measured the ability of DENV 4 FL NS5 mutants to 
initiate the synthesis of DENV 4 -ssRNA (anti-sense strand) using the 
(+)ss 5´UTR-3´UTR viral subgenomic RNA as template (Figure 3.6). 
The RdRp and viral RNA were initially incubated for about 20 min 
before the 2 hr incubation time point.  
 
Figure 3.6: Simplified structure of DENV 4 5’UTR-3’UTR RNA template used in  
FAPA de novo initiation assay 
The ~10.8 kb genomic viral RNA template is made up of 5’UTR-3’UTR end with 19 nt 
open reading frame (ORF) nucleotide sequence located between the two ends. 
 
  
100 nucleotides 400 nucleotides 
19 nt  linker   




 Results showed that DENV 4 FL NS5 N610A and D664A 
mutants exhibited dramatic decrease of 99.72% and 100.38% 
respectively in enzymatic activity as compared to the WT (Table 3.3). 




These two residues form a major part of the catalytic domain of RdRp 
enzyme thus mutations to Ala may have impeded the de novo initiation 
process. This gives an insight into the relevance of N610 and D664 in 
viral replication. In contrast G605A and W796A showed slight increase 
of 6.84% and 25.24% respectively in RdRp activity. This could imply 
that residues G605A and W796A may not be essential for polymerase 
activity. Mutation of residues F399, K402, N493 and Y607 to Ala 
showed dramatic decrease of 67%, 92%, 86% and 78% in RdRp 
activity respectively whiles F486A showed an intermediate decrease of 
about 35% as compared to WT.  
 
 
3.4.2 FAPA Elongation Assay 
 The elongation of DENV 4 FL NS5 mutant polymerases were 
assessed using homopolymeric RNA primer template 3´UTR-U30 RNA 
(5´-bio-U30-AACAGGUUCUAGAACCUGUU--3´). The presence of U30 
nucleotide sequence in the RNA primer provides a template for NS5 to 
easily add on the complimentary ATP nucleotides in the form of BBT-
ATP (Figure 3.7). 
Slight difference in results was obtained from both de novo 
initiation and elongation activities of DENV 4 FL NS5 mutants (Table 
3.3 B). The only exception was Y607A which showed 15.96% minor 
increase in elongation activity as compared to the significant decrease 
of 78.29% in de novo activity implying that the aromatic side chain is 
not essential for elongation activities but might play a key role in de 








Figure 3.7: Structure of 3’UTR-U30 RNA primer template for FAPA elongation assay 
The primer is made up of 10 residues at the 3' end (AGAACCUGUU) complementary  
to the underlined 10 nucleotides (AACAGGUUCU) of DENV genome, followed by  




Figure 9. (A)Schematic diagram of the UTR-U30 RNA template used in elongation FAPA. TheU30
indicates that the presence of 30 Uracil nucleotides at the 5’ end. As the 3’ end (underlined region) is 
complementary to the nucleotides in front of it (bolded), the 3’ end folds back to form a hairpin structure. 
The 3’ ends acts as a primer for the RdRp domian to add BBT-ATP, using the U30 as the template. 
(B) Schematic diagram of DENV-4 5’UTR-3’UTR RNA template used in de novo FAPA. 
The template consist of DENV-4 5’ UTR, followed by a partial sequence of DENV-4 NS5 ORF (19 
nucleotides long) and DENV-4 3’ UTR. 
Addition of BBT-ATP 
by the NS5 RdRp
domain
5’ UTR 3’ UTR






 Interestingly, G605A was the only mutant which showed a 
decrease in elongation activity as compared to de novo initiation. 
G605A exhibited a dramatic decrease of 29% elongation activity of the 
WT as compared to the slight increase of 6.84% during de novo activity. 
 
 
Table 3.2: Categories of Change in DENV 4 NS5 FL Mutant 
Proteins Enzymatic Activities as Compared to WT 
Categories 
of change 
Insignificant    








% activity  
X≤15% 15%≤X≤30% 30%≤X≤50% X≥50% X≥80% (X) 








Table 3.3: RdRp Enzyme Activity of DENV 4 FL NS5 Mutants 




% difference in 
activity between 
mutants and WT 
Categories of 
change 
2 hrs  
WT DENV 4 FL NS5  100   -   - 
F399A 32.78 ± 9.21 67.22 significant  
K402A 7.02 ± 3.28 92.98 very dramatic 
F486A 64.90 ± 10.44 35.1 intermediate 
N493A 13.34 ± 4.13  86.66 very dramatic 
G605A 106.84 ± 12.09 6.84 insignificant 
Y607A 21.71 ± 4.72 78.29 significant  
N610A 0.28 ± 0.42 99.72 very dramatic 
D664A -0.38 ± 0.37 100.38 very dramatic 
W796A 125.24 ± 10.29 25.24 minor  
The mean standard deviation (S.D.) of the average value of all FAPA elongation 
experiments were calculated as shown above. 
 
 




% difference in 
activity between 
mutants and WT 
Categories of 
change 
2 hrs  
WT DENV 4 FL NS5  100     -    - 
F399A 40.57 ± 7.09 59.43 significant  
K402A 38.49 ± 9.68 61.51 significant  
F486A 79.63 ± 1.94 20.37 minor  
N493A 29.56 ± 10.74 70.44 significant  
G605A 83.93 ± 14.78 16.07 minor  
Y607A 126.48 ± 23.12 26.48 minor  
N610A 5.67 ± 3.79 94.33 very dramatic 
D664A 7.67 ± 5.69 92.33 very dramatic 
W796A 124.13 ± 18.33 24.13 minor  
The mean standard deviation (S.D.) of the average value of all FAPA elongation 








The effects of Ala mutation was as well profound in N610A and 
D664A which again exhibited a very dramatic decrease of 95.67% and 
95.07% in enzymatic activity whilst W796A maintained an intermediate 
increase of 18% enzymatic activity of the WT giving an indication that 
W796A residue is not essential for FL polymerase activity. Mutation of 
residues F399A, K402A and N493A showed a dramatic decrease of 
58%, 73% and 78% respectively in the elongation activity of RdRp 
whiles F486A showed an intermediate decrease of about 19%.  
 
 
3.5 Differential Scanning Fluorimetry 
 Stability and melting temperatures (Tm) of DENV 4 FL NS5 
mutants was assessed using thermofluoresence assay. This was to 
ensure that the observed changes in RdRp enzyme activities of DENV 
4 FL NS5 mutants were not due to protein instability. Sypro® Orange 
fluorescent dye in the reaction mixture binds to the exposed 
hydrophobic regions of proteins as they unfolded during heating. The 
binding increases fluorescence (RFU) intensity detected at 
excitationmax 485 nm and emissionmax 625 nm.  
 Results showed that there were no significant shifts in the 
melting temperatures of DENV 4 FL NS5 mutants as compared to WT 
(Figure 3.8), indicating that the structural integrity of the proteins were 
similar. The sharp curve on the x,-y axis as shown indicated the Tm of 
a proteins. The more stable proteins such as F399A, K402A, G605A, 
Y607A, D664A and W796A have higher Tm than the 37.4 °C obtained 




from the WT. This suggests that protein stabilization occurred as a 
result of the mutation. 
 




















Change in Tm 
between mutants 
and WT 
WT DENV 4 FL NS5  37.4    - 
F399A 39.1 1.7 
K402A 38 0.6 
F486A 37 -0.4 
N493A 37.2 -0.2 
G605A 39 1.6 
Y607A 38 0.6 
N610A 37.6 0.2 
D664A 39 1.6 










Figure 3.8:  Thermofluorescence assay results 
A) Graphical representation of thermal shifts for DENV 4 NS5 mutants and WT using  
K402A and D664A as representatives. Tm of proteins is shown on the sharp curves at x,-y  











3.6 Measurement of Steady-state Kinetic Parameters 
 Steady-state kinetic studies of RNA Km and NTP Km substrates 
were carried out for some DENV 4 FL NS5 mutants. This was to 
understand the difference in enzyme activity of selected mutants 
compared to WT. Mutant proteins chosen were F399A, N493A and 
Y607A as they showed extreme changes in de novo initiation activity. 
Mutants K402A, N610A and D664A were not selected for this assay 
because; there would be no measurable activity for their kinetic 
parameters due to their very low de novo activities. The principle 
behind this assay was adopted from de novo initiation experiment. It 
was used to access the kinetic parameters by the incorporation of 
serial dilution of substrates at lowering concentrations. 
Vmax was used to determine the efficiency of DENV 4 NS5 
protein enzyme. It represents the maximum velocity or rate of catalysis 
of the polymerase enzyme which subsequently leads to the replication 
of viral RNA strand. kcat which is also termed as the catalytic rate 
constant or the substrate turnover number is calculated directly from 
Vmax and indicates the ability of the enzyme to incorporate free 
nucleotides onto the viral RNA at differing concentrations. Thus, higher 
values in kcat, is as a result of an increase in the rate of enzyme 
catalysis. Km was also used to determine the RdRp enzyme affinity for 
the substrates. Thus, a higher Km value could result in a lower rate in 
affinity of the enzyme to the substrates. 
 
 




3.6.1 RNA Km Studies 
 DENV 4 FL NS5 mutants N493A and Y607A had higher folds in 
Km of 2.3 and 3.8 respectively whilst F399A had a slight increase of 1.2 
fold for RNA substrates as compared to WT (Figure 3.9). This resulted 
in a lower enzyme affinity and efficiency leading to a lower turnover 
number of 0.04, 0.03 and 0.03 units respectively. Nevertheless, F399A 
exhibited the highest turnover rate as compared to the other two 
mutants and this was in line with the FAPA de novo (Table 3.3 A).  














Average DENV 4 FL NS5 F399A N493A Y607A 
Vmax (nM/min) 15.65 ± 4.67 3.68 ± 1.67 2.86 ± 0.83 2.61 ± 0.71 
Km (nM) 53.66 ± 11.80 67.59 ± 0.21 122.45 ± 22.27  204.1 ± 69.01 
kcat (min
-1
) 0.16 ± 0.05 0.04 ± 0.02 0.03 ± 0.01 0.03 ± 0.01 
 










Figure 3.9: Steady-state Kinetic Parameters: RNA Km  
A) Graphical representation of enzyme kinetics using Graphpad Prism software. The 
substrate inhibition curves showing correlation between decreasing RNA substrate 
concentration and amount of BBT-CTP incorporation per min. B) The mean S.D of the 
average value of all experiments were calculated as shown above. Km and Vmax 
steady state parameters were obtained from Graphpad Prism software. Apparent Vmax 
as seen in the table was multiplied by 4 as the software calculated Vmax based on 
BBT-CTP incorporation alone without including the other NTPs. kcat was measured by 
Vmax /[enzyme].  
 




3.6.2 NTP Km Studies 
 DENV 4 FL NS5 mutants F399A and N493A had 1.12-fold and 
2.29-fold increase in Km for NTP substrates as compared to WT (Figure 
3.10). N493A had a lower enzyme affinity but was able to incorporate 
nucleotides for RNA replication efficiently than F399A resulting in a 
higher turnover rate of 0.11 by N493A as compared to 0.08 obtained by 
F399A. 
  
Figure 3.10: Steady-state Kinetic Parameters: NTP Km  
A) Graphical representation of enzyme kinetics using Graphpad Prism software. The 
substrate inhibition curves showing correlation between decreasing NTP substrates 
concentration and amount of BBT-CTP incorporation per min. B) The mean S.D of 
the average value of all experiments were calculated as shown above. Km and Vmax 
steady state parameters were obtained from Graphpad Prism software. Apparent 
Vmax as seen in the table was multiplied by 4 as the software calculated Vmax based 


















Average DENV 4 FL NS5  F399A N493A 
Vmax  (µM/min) 15.99 ± 2.90 7.78 ± 1.83 10.83 ± 0.27 
Km  (µM) 2.17 ± 0.54 2.44 ± 0.75 4.98 ± 1.48 
kcat (min
-1
) 0.16 ±  0.03 0.08 ± 0.02 0.11 ± 0.002 
 














3.7 Production of Recombinant Viruses 
 To examine the biological relevance of DENV 4 FL NS5 mutants, 
mutations were introduced into DENV 2 TSV01 infectious virus. Mutant 
samples were selected upon presenting an enzyme activity of less than 
50% as compared to WT during de novo initiation of RNA replication. 
Mutants F399A, K402A, N493A, Y607A, N610A, D664A and W796A 
were chosen to determine their viral protein synthesis, plaque 
morphology and viral production whilst W796A served as control. All 
seven Ala mutant clones of DENV 2 FL NS5 were generated using 
TSV01-F subclone plasmid (bearing FL NS5 cDNA) as template.  
 DENV 2 TSV01-F subclone plasmid containing NS5 insert of 
positive  mutations from F399A, N493A, N610A, D664A and W796A 
were successfully cloned into pACYC-FL TSV01 plasmid (bearing 
infectious WT FL DENV2 TSV01 cDNA) for production of in-vitro 
transcribed (IVT) FL viral RNA (Figure 3.11). Many attempts to clone 
DENV 2 TSV01-F subclone K402A and Y607A into pACYC-FL TSV01 
plasmid were performed however, none was successful. 






Figure 3.11: Cloning of pACYC-FL TSV01 and viral IVT RNA production 
 Lane 1 from Figures 3.10 A, B and C 0.8% agarose gel contained 100bp DNA ladder 
(NEB, U.S.A.). Lane 7 from Figures 3.10 A and B correspond to the DENV 2 WT 
pACYC (control). A) Lane 2 - 6 represents the expected 4.9 Kb and 9.5 Kb positive 
ligated clones from F399A, N493A, N610A, D664A and W796A after ClaI and XbaI 
restriction enzyme digestion. B) Positive ligated DNA samples from A were further 
tested by PCR using primers TSV01-9583V-FOR and TSV01-10723C-REV. Lane 2 -
6 represents expected 1kb band PCR product. C) 11kb IVT of FL viral RNA was 
produced from linearized DENV 2 pACYC positive clones and WT. 
 
 
3.7.1 Indirect Immunofluorescence Assay  
This assay was used to determine the presence and location of 
DENV 2 viral antigen in cells by immunofluorescence after 
electroporation of viral RNA. BHK 21 (US) cells were transfected with 
viral RNA from mutants F399A, N493A, N610A, D664A, W796A and 




WT. Presence of viral envelope protein in the cell cytosol was detected 
by the green fluorescence produced by α-mouse-FITC-labeled goat 
anti-mouse IgG secondary antibody bound to anti-mouse 4G2 primary 
antibody (Figure 3.12 A). Anti-rabbit-NS5 primary antibody was used to 
detect expression of NS5 protein in the cell nucleus.  NS5 positive 
cells were detected by the red fluorescence produced by Alexa Fluor 
594 goat anti-rabbit IgG secondary antibody which binds to the primary 
antibody (Figure 3.12 B). Presence of double-stranded (ds) viral RNA 
in cell cytosol was also detected with α-mouse-FITC-labeled goat anti-
mouse IgG secondary antibody which produced green fluorescence 
upon binding to anti-mouse-dsRNA primary antibody (Figure 3.12 B). 
Dapi was used to stain the cell nucleus. It binds to the A-T regions of 
DNA which subsequently produced blue-fluorescent (Figure 3.12 A and 
B). 
The expression of viral envelope, NS5 protein and dsRNA in IFA 
positive cells were detected for W796A and WT on days 1, 2, 3 and 4 
post-transfection. Also, IFA positive cells increased consistently from 
day 1 to 4 incubation time period. However, the number of positive 
cells from W796A transfected RNA differed by less than ~50% from the 
WT. No infectious virus or IFA positive cells were recovered from 
F399A, N493A, N610A and D664A RNA transfection (Figure 3.12 A 
and B). IFA for W796A was done twice to ensure reproducibility since 
results obtained during the in vitro studies was inconsistent with the 
number of IFA positive cells obtained as compared to the WT. 





Figure 3.12: Effects of mutagenesis on viral replication of DENV 2 pACYC 
TSV01 infectious clone.  
A) A picture showing merged colours of green fluorescence produced by α-mouse-
FITC-labeled goat anti-mouse IgG is used to detect expression of viral envelope 
protein in the cell cytosol and blue fluorescence produced by DAPI to show the cell 
nucleus. B) A picture showing merged colours of green fluorescence produced by α-
mouse-FITC-labeled goat anti-mouse IgG is used to detect presence of double-
stranded (ds) viral RNA in cell cytosol, red fluorescence produced by Alexa Fluor 594 
goat anti-rabbit IgG for detection of expression of NS5 protein in the cell nucleus and 
blue fluorescence produced by DAPI to show the cell nucleus. C) Plaque morphology 
of BHK 21 (NITD) cells. Plaque formation detected for only WT and W796A. N.D. 
implies, no plaque was detected. 
 




3.7.2 Plaque Assay 
 This assay was used to quantitatively measure the infectious 
virus particles produced by DENV 2 mutant and WT virus RNA from 
culture media of electroporated BHK cells collected at day 4 post-
transfection. The methyl cellulose overlay media was used to cover the 
cell monolayer to prevent the spread and diffusion of virus released 
from one infected cell to another. Plaques are clear areas developed in 
the circle monolayer as DENV 2 infected BHK-21 (NITD) cells are 
lysed by the virus.  
These cells were observed to produce WT virus titre of 1.15x106 
pfu/ml whilst W796A also produced virus titres of 5.5x103 pfu/ml at 96 
hrs post-infection. Plaque assay for W796A was also done thrice to 
ensure reproducibility since pfu obtained was about half of the WT. 
Additionally, a 7 days incubation period was carried out for both 
W796A and WT (data not shown). Plaques obtained for W796A was as 
well incomparable to WT.  
There were no plaques detected from mutants F399A, N493A, 
N610A and D664A RNA transfected cells (Figure 3.12 C). The 
observed plaques from W796A were seen only at 10-1 dilution and 
were faint as compared to the distinct plaques formed by WT from 10-1 
to 10-4 viral titre dilutions (data not shown). Plaque morphology study 
obtained for mutants and WT were in line with IFA results. These 
results suggest that residues F399, N493, N610 and D664 in the RdRp 
cavity of DENVs are essential for viral replication. 
 





DISCUSSION AND CONCLUSION 
 Amino acids lining the RdRp pocket (Figure 1.7 C) were 
selected and mutated to Ala based on previous findings by X-ray 
crystallography. Several novel molecules were found to inhibit this 
enzyme by binding to specific sites in the DENV 3 NS5 RdRp domain. 
Eight residues: F398, K401, F485, N492, G604, Y606, N609 and D663 
interacted with NITD567compound, NITD whilst two residues: N492 
and W795 interacted with NITD329 compound, NITD (Table 1.1). N493 
was the only residue we found interacting with both compounds in the 
RdRp binding pocket through different chemical reactions. 
  These amino acid residues are conserved in all 4 DENV 
serotypes (Figure 1.8) and other flavivirus such as Japanese 
Encephalitis Virus (JEV), Yellow Fever Virus (YFV) and West Nile Virus 
(WNV). This finding indicates that these amino acids may play an 
important role in viral RNA replication and propagation and therefore 
could be a possible target for drug discovery. The only exception was 
G605, it showed conservation in only DENV 1, 3 and 4 serotypes and 
replaced by V605 which also showed conservation in DENV 2, JEV, 
YFV and WNV. 
 Using both biochemical assays and reverse genetic analysis, we 
then characterised the mechanism of action of these inhibitors. This 
was to enable us determine the biological importance and biochemical 
properties of these amino acid residues for both in vitro polymerase 




activity and as well for replication fitness in the context of the DENV 2 
TSV01 infectious virus. We selected DENV serotype 4 for DENV in 
vitro polymerase activity studies due to its stability (Zou et al., 2011). 
DENV 2 serotype was used for the infectious virus study because, at 
the time of these experiments, our laboratory did not have a FL DENV 
4 infectious clone to perform reverse genetics studies.  
 
 
4.1 DENV 4 NS5 RdRp Characterization for In vitro Polymerase 
Activity 
 Prior studies to elucidate mechanism of flavivirus NS5 RdRp 
activity have been demonstrated in various in vitro biochemical 
systems (Tan et al., 1996; Ackermann and Padmanabhan, 2001; 
Guyatt et al., 2001; Selisko et al., 2006).  Thus, to determine the in vitro 
polymerase activity of our amino acid residues of interest, all nine 
DENV 4 FL NS5 mutant protein enzymes were generated following 
site-directed mutagenesis of residues to Ala and subsequent bacterial 
expression as indicated in the previous chapters.   
Protein yields could vary due to several factors such as: the 
amount of DNA used for transformation, total volume of LB media used 
during incubation and the amount of lysate used for the purification 
process. We retained a high protein yield from most of the FL NS5 
mutant proteins (Table 3.1) which were as well comparable to ~10 -15 
mg yield per liter of expression culture of WT FL NS5 (previously 
expressed in NITD). The only exception was F399A and F486A. 




Although the same experimental conditions were used for all mutants 
during the protein expression and purification process, F399A and 
F486A retained very low yields even upon repeating the process for the 
second time. Nevertheless, their low yield did not affect protein stability 
and enzyme activity. 
 
 
4.1.1 Effects of Mutations on NS5 RdRp De novo Initiation and 
Elongation Activities  
 DENV utilizes primer-independent (de novo) RNA synthesis 
initiated at ATP-specific priming site of the 3´ end in the viral RNA 
template. Upon binding of the RNA template to RdRp domain, de novo 
initiation process begins with the addition of ATP initiating nucleotide to 
the RNA priming site (i) followed by the first GTP nucleotide substrate 
which binds to the nucleotide binding site (i+1). The binding of GTP 
results in the formation of a phosphodiester bond with the first ATP 
(Figure 4.1).  
The Mg2+ metal ion is required for efficient incorporation of ATP 
to the priming site (Selisko et al., 2012). Additionally, RdRp residues 
R472, S710 and R729 are essential in the binding of triphosphate 
(Selisko et al., 2006). DENV NS5 RdRp specificity for ATP and GTP, 
during de novo initiation, is required for efficient NS5 MTase activity. 






Figure 4.1: Schematic representation of DENV RdRp de novo RNA synthesis
  
A model adapted from Choi and Rossmann, 2009. The RNA template is shown in 
blue boxes and nucleotides (NTP) required for RNA sythesis are shown in green A) 
De novo initiation begins with the incorporation of DENV initiating ATP nucleotide (i) 
shown in green, followed by the addition of GTP nucleotides (i+1). B) Formation of 
the de novo initiation complex. C) Replication switches to elongation upon 
conformational changes of the enzyme. (Reprinted from Current Opinion in Structural 
Biology: volume 19, Choi, K.H., and Rossmann, M.G., RNA-dependent RNA 




The dinucleotide (pppAG) accumulated during the de novo 
initiation process, is an optimal primer required for elongation process 
(Selisko et al., 2012). During the elongation phase, RdRp switches 
from a closed conformation to an open form (Selisko et al., 2006; 
Selisko et al., 2012). The nucleotidyl transfer process is required to 
generate a 5´-3´complementary RNA product. 
 Upon mutating the nine selected residues to Ala, we decided to 
test for the RdRp activity of the mutated enzyme. Knowing that DENV 
RNA replication utilizes both de novo initiation and elongation steps 
(Malet et al., 2008), an assay developed by Niyomrattanakit and 
coworkers was used to analyze the mutant polymerase activity for both 
processes (Niyomrattanakit et al., 2010). 
  
 
A B C 




4.1.1.1 F399A and K402A 
 DENV 4 FL NS5 residues F399 and K402 were found to be 
located within the α/β region of the nuclear localisation sequence (NLS) 
(Figure 1.8; Yap et al., 2007). NLS is positioned at the amino terminal 
region of RdRp and consists of β NLS with residues 316 to 368 and α/β 
NLS sequences with amino acid residues 369 to 415 (Yap et al., 2007; 
Malet et al., 2008).  The α/β NLS residues are situated within the 
fingers and palm domain (Figure 1.7 A) giving an indication that it might 
play a role in RdRp enzyme activity.  
 In our study, we observed that F399A and K402A mutant 
residues demonstrated more than 60% loss of enzyme activity in both 
de novo initiation and elongation steps of RNA synthesis. Indicating 
that, the aromatic and basic residues of these N-terminal domain 
amino acids are involved in a step common to both modes of synthesis 
or polymerase reaction since the effects of Ala mutations were similar 




4.1.1.2 F486A and N493A 
 Amino acid residues F486 and N493 were found to be located in 
the α helix terminal end of the finger subdomain (Yap et al., 2007). The 
finger subdomain is known to be more mobile as compared to the palm 
and thumb subdomains. F486A mutant presented a minor change in 
polymerase activity for both de novo initiation and elongation steps. 




Perhaps, this gives an indication that the hydrophobic aromatic ring of 
F486 does not play any significant role during viral RNA synthesis. 
 Interestingly, we observed that mutation of N493 residue to Ala 
resulted in a very dramatic change of about 80% decrease in both 
RdRp de novo initiation and elongation processes. This may be due to 
the close its proximity of about four amino acids to the palm domain. 
Thus, Ala mutation of N493 affected its characteristic hydrophilic 
interactions which were possibly required by the other neighboring 
residues in the palm subdomain for enzyme activity.  
 
 
4.1.1.3  G605A, Y607A, and N610A 
 The palm subdomain consists of amino acid residues 497 to 542 
and then 601 to 705 of which our mutated residues: G605, Y607 and 
N610 are located (Figure 1.8). The three mutated amino acids are 
located precisely at the α16 region of the palm subdomain (Yap et al., 
2007). We initially stated that all amino acids were conserved with the 
exception of G605. Thus, it was not surprising when G605A mutant 
enzyme presented its de novo and elongation polymerase activity 
comparable to WT. This suggests that perhaps, the functional group of 
G605 residue is not required for or affected by RNA replication. 
 On the contrary, both de novo and elongation activities were 
abolished by mutant N610A giving an indication that its functional 
hydrophilic group is required by the RdRp enzyme for both de novo 




initiation and elongation activities. Interestingly, Y607A rather showed 
an increase of over 100% in RdRp elongation activity and 80% 
decrease in de novo activity of the WT. This implies that Y607 residue 
is important for de novo initiation and does not affect the elongation 
process. During RNA de novo initiation, Flaviviral RdRp assumes a 
closed conformation due to the arrangement of the domain thereby 
constraining the volume of the template-binding channel and permitting 
only single-stranded RNA to enter the active site (Choi and Rossmann, 
2009). Thus, we suggest that Y607 might be required for de novo 
synthesis by playing a role in contributing to the closed conformation of 
RdRp thereby stabilizing the initiation complex.  
 When Ranjith-Kumar and co-workers assessed the replicative 
ability of Bovine viral diarrhoea virus (BVDV) GTP binding site residues 
of C497, S498, and R517 upon mutation, they observed an obliterate 
effect in de novo initiation activity and about 2-10 fold reduction in 
elongation activity confirming the role of GTP binding site in de novo 
initiation (Ranjith-Kumar et al., 2002). Thus, it could also be possible 
that Y607 may be required for efficient DENV de novo initiation process 





 Mutation of D664 of amino acid residue to Ala resulted in a total 
loss of the polymerase enzyme activity. This gives an indication that 
the residue is essential for polymerase reaction. Effects of Ala mutation 




were similar to both de novo initiation and elongation of RNA 
replication thus we suggest that D664 may be involved in a step 
common to both modes of synthesis.  
 D664 is located in motif C of the palm subdomain (Yap et al., 
2007). This residue forms part of the three amino acids catalytic tirad 
known as the Glycine-Aspartate-Aspartate (GDD) motif (Figure 1.8; 4.2) 
of which their activities are required for the initiation of the 
polymerisation reaction.  
 
 
Figure 4.2: Ribbon diagram showing the conserved motifs in RdRp catalytic 
domain  
Motif C, coloured in red, contains the G662-D663-D664 (GDD) catalytic triad for 
coordinating Mg
2+
 ions. The priming loop of which W796 forms part is coloured in pink 
(Yap et al., 2007).  
 
The aspartic residue of the GDD motif is responsible for 
coordinating the two catalytic magnesium (Mg2+) ions, essential for 
dsRNA 
exit 




stabilising the initiating nucleotide at the initiating site of the RNA 
template (Malet et al., 2008; Choi and Rossmann, 2009). During de 
novo initiation, the NTPs are positioned first at the priming site then 
secondly the catalytic site surrounding the GDD residues (Bressanelli 




 W796 forms part of the priming loop in the thumb domain of 
DENV and other Flavivirus RdRps (Figure 4.2). The loop have been 
found to play an important role in de novo initiation process and it is 
made up of amino acid residues 782 to 809 (Yap et al., 2007). It 
encircles the catalytic site and is proposed to control the access and 
exit of substrates into the active site and also enhance the stabilization 
of the de novo initiation complex by stacking interactions (Malet et al., 
2008; Choi and Rossmann, 2009; Selisko et al., 2012). Most especially, 
amino acids T794 to A799 of the priming loop have been suggested to 
provide ATP-specific priming site for RdRp activity (Selisko et al., 2012).  
 Butcher and co-workers in their studies identified the amino acid 
Y630 in BVDV RdRp to be responsible for stacking interactions with 
the base of the priming NTP (Butcher et al., 2001). Malet et al., 2008 
then suggested that DENV 3 RdRp residues W795 or H798 could as 
well be involved in the stacking stabilisation process of DENV since no 
equivalent of tyrosine group exists in Flavivirus RdRp (Malet et al., 




2008). But surprisingly, upon mutation to Ala, we realized that DENV 2 
W796A which corresponds to DENV 3 W795A presented an equal 
RdRp enzyme activity as compared to the WT. Results obtained from 
Ala mutation were similar to both de novo initiation and elongation 
steps of RNA replication. Indicating that the W796A may not be 
involved in the stacking stabilisation of the priming loop during de novo 
initiation and also, this residue is not affected by the elongation step. 
Indeed, our results obtained for W796A was as well reflected in similar 
studies conducted by Selisko et al., (2012).  In view of that, we suggest 
that H798 plays an essential role in providing an initiation platform for 








4.1.2 Stability of DENV NS5 RdRp mutants 
 A biophysical study was performed for all nine RdRp mutants. 
This was to ensure that the de novo initiation and elongation 
polymerase activities of the mutants were not affected by protein 
instability. For instance, a decrease in RdRp activity may occur when 
proteins are destabilized by the mutations thereby disrupting the 
integrity of the protein structure. From this study, we realised that the 
melting temperature (Tm) of DENV FL NS5 mutant proteins recorded 
negligible shifts as compared to WT (Figure 3.8 B). This gives an 
indication that the structural integrity of the mutant proteins was intact. 
Hence, protein stability cannot explain the decrease in enzyme activity 




for F399A, K402A, F486A, N493A, G605A, Y607A, N610A and D664A 
mutants regarding their de novo and/or elongation activities.   
 
 
4.1.3 Effects of NTP Km and RNA Km on DENV FL NS5 Mutants 
 The steady-state kinetic parameters for NTP and RNA 
substrates were measured to understand reasons behind the 
difference in RdRp enzyme activities. The polymerase enzyme, as 
previously discussed, is required for the polymerization (replication) of 
new viral RNA strand against an existing RNA template. Thus the 
enzyme utilizes nucleotides (NTPs) and RNA as substrates for its 
catalytic activity. We expected to see an increase in enzyme activity as 
substrate concentration increased until the enzyme was saturated of 
which an increase in substrate concentration does not affect enzyme 
activity (Vmax).  
 Ala mutations of F399, N493 and Y607 did not yield an 
appreciable change in Km, Vmax and turnover number for RNA 
substrates (Figure 3.9). Note that from the Km generated by the 
Graphpad prisim software, the higher the Km of an enzyme, the lower 
the enzyme affinity for the RNA substrate resulting in a lower or no 
enzyme catalysis and substrate turnover. Thus, Ala mutations of F399, 
N493 and Y607 in DENV NS5 RdRp resulted in a lower turnover 
number of approximately 20-25% of WT, implying that the mutations 
might have affected RNA synthesis.  




 Further experiment to determine the mutant protein enzyme 
kinetic parameters using NTP as substrate, yielded no measurable 
results for Y607A. But, F399A and N493A protein enzymes were able 
to incorporate NTPs during de novo replication efficiently than in the 
case of RNA Km/kcat studies (Figure 3.9; 3.10). Nevertheless, the 
turnover rate of 50% and 69% obtained for F399A and N493A 
respectively, was not comparable to WT, suggesting that residues 




4.2 Characterization of DENV 2 TSV01 NS5 Mutants 
 Upon successful characterization of the in vitro biochemical 
properties of DENV 4 FL NS5 RdRp mutant proteins and their effects 
on RNA replication activities, we then decided to carry out further 
functional studies on F399A, K402A, N493A, Y607A, N610A, D664A 
and W796A mutants. This was due to their significant changes in RdRp 
de novo activity. As previously discussed, DENV 4 mutants F399A, 
K402A, N493A, Y607A, N610A and D664A recorded a decrease of 
more than 70% in de novo RdRp activity whilst W796A retained an 
increase in RdRp activity of 25% than the WT.  
 In order to gain more insight into the biological importance of 
these RdRp amino acid residues during RNA replication, functional 
relevance of the mutants in the context of DENV 2 infectious clone 
were probed into. IVT RNA of DENV 2 pACYC TSV01 infectious clone 




mutants were successfully generated through SDM and cloning with 
the exception of K402A and Y607A. We initially performed 
Immunofluorescence assay (IFA) to detect and compare expression of 
viral envelope, NS5 protein and double-stranded (ds) viral RNA on 
days 1, 2, 3 and 4 post-transfection. Also, virus titers were determined 




4.2.1 Expression of Viral Proteins and RNA 
 Mutants F399A, N493A, N610A and D664A did not produce IFA 
positive cells during the entire four days incubation period since they 
had already shown more than 85% decrease in RdRp activity during 
our in vitro studies. Identification of α and β nuclear localisation 
sequences (NLS) in the C-terminal RdRp domains of NS5 is 
considered to be responsible for the nuclear localisation. The 
colocalisation of NS5 in the nucleus as observed by other research 
groups (Buckley et al., 1992; Kapoor et al., 1995; You and 
Padmanabhan, 1999; Pryor et al., 2007; Yap et al., 2007; Malet et al., 
2007; Malet et al., 2008) was also confirmed in our studies (Figure 3.12 
B). Having known the major role of NS5 in RNA replication and its 
interaction with the replicative complex in the cytosol, its nuclear 
localisation throughout the four days incubation period, remains elusive 
although it is known to play a role in pathogenesis.  




 It has been proposed that colocalisation of NS5 to the cell 
nucleus is required for the modulation of host gene factors thereby 
promoting viral RNA synthesis (Pryor et al., 2007). Studies conducted 
by some groups have shown that nuclear trafficking of NS5 occurs with 
the aid of chromosome region maintenance 1 (CRM1) exportin 
receptor through recognition of the leucine-rich nuclear export signal on 
NS5 RdRp (You and Padmanabhan, 1999; Pryor et al., 2007; Ding et 
al., 2010). Rawlinson et al., (2009), have demonstrated that inhibition 
of exportin receptors affected viral production and subsequent 
decrease in IL-8 chemokine production which is known to play a role in 
DENV pathogenesis. F399A which presented 67% decrease in de 
novo RdRp activity was as well deficient of IFA positive cells. F399 
mutation might have restricted the transport of NS5 to the nucleus, 
since it also forms part of NLS, thereby preventing the expression of 
viral particles. 
 We identified W796A as the only mutant that presented 
expression of DENV viral envelope, NS5 protein and dsRNA in IFA 
positive cells since it behaved as the WT in our in vitro studies (Figure 
3.12). As shown in our data, localization of dsRNA was found to be at 
the perinuclear region of the cytosol, NS5 was found to be present in 
the nucleus and expression of viral envelope was found to be 
distributed in the cytosol. Expression of viral proteins and dsRNA in IFA 
positive cells increased consistently from day 1 to day 4 incubation 
time. Surprisingly, we identified only about 50% IFA positive cells for 
W796A as compared to WT (Figure 3.12 A and B) even though IFA 




was repeated twice to confirm our finding regarding Ala mutational 
effects on the residue. Giving an indication that Ala mutation of 
Tryptophan at position 796 had a moderate impact on RNA synthesis 




4.2.2 Plaque Morphology 
 W796A RNA generated an infectious DENV with plaque 
morphology whilst no infectious virus was recovered by F399A, N493A, 
N610A and D664A (Figure 3.12). Just as in the case of IFA results, we 
observed a decrease in plaques obtained for W796A as compared to 
WT. Plaque assay was repeated thrice for W796A and WT of which 
their average virus titres were determined. WT DENV continuously 
recorded ~6x104 pfu/ml viruses more than W796A.  
 We further decided to repeat the experiment by increasing the 
incubation time point for W796A and WT to day 7 to verify whether 
W796A could recover comparable virus titres as WT as in the case of 
our in vitro studies. No significant difference in results was obtained for 
W796A upon incubation till day 7 (data not shown). Observed plaques 
were obtained at only 10-1 dilution as compared to plaques formed from 
10-1 to 10-4 dilutions of WT just as in the case of the 4 days incubation 
time point. Nevertheless, both WT and W796A virus induced 
cytopathetic effect (CPE) which enabled us to identify viral infection by 
examining the characteristic CPE produced. However, significant CPE 













4.3 Summary of Discussion 
 In our studies, we had successfully characterized the in vitro 
properties of nine recombinant DENV NS5 RdRp domain mutants with 
respect to their effects on RNA de novo initiation and elongation. We 
identified the steady-state kinetic parameters of some selected mutants 
and protein stability of all mutants was also evaluated. We further 
characterized the replication fitness in the context of the DENV 2 
TSV01 infectious virus for selected mutants to quantify viral titre 
production and as well the expression of viral envelope, NS5 protein 
and dsRNA in BHK-21 mammalian cell lines. This was to understand 
the mode of action, binding sites and potency of mutants in cellular 
context.   
Among all nine mutated amino acid residues; F486A, G605A 
and W796A do not play a vital role in RdRp polymerase activity. 
Nevertheless, these residues may be important for other viral activities 
and also structurally important due to their conservation across most of 
flaviviruses and as well, DENV serotypes. W796A had the greatest in 
vitro RdRp de novo initiation and elongation activities but, could not 
generate equivalent amount of IFA positive cells and infectious virus 
with plaque morphology as the WT. The reason for this discrepancy of 




W796A is unclear although it could imply that the residue might play a 
role in viral replication through a nonenzymatic mechanism. Table 4.1 
summarises results obtained from the biological, biophysical and 
biochemical properties of all amino acid residues in this study. 
 





While it is clear that conserved sequences and structures of 
DENV play an important role in regulating viral RNA synthesis, our 
understanding of the role of NS5 in RNA synthesis and pathogenesis 
might be rudimentary. Further revertant analysis can be undertaken for 
DENV NS5 RdRp mutant proteins to check for possible mutations that 
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NS5  100 100 37.4 15.65 53.66 0.16 15.99 2.17 0.16  ++++ Yes 
F399A 67.22 59.43 1.7 3.68 67.59 0.04 7.78 2.44 0.08 N.D. N.D. 
K402A 92.98 61.51 0.6  -  -  -  -  -  -  -  - 
F486A 35.10 20.37 -0.4  -  -  -  -  -  -  -  - 
N493A 86.66 70.44 -0.2 2.86 122.5 0.03 10.83 4.98 0.11 N.D. N.D. 
G605A 6.84 16.07 1.6  -  -   -  -  -  -  -  - 
Y607A 78.29 26.48 0.6 2.61 204.1 0.03  -  - 
 
 -  - 
N610A 99.72 94.33 0.2  -   -  -  -  -  - N.D. N.D. 
D664A 100.38 92.33 1.6  -  -  -  -  -  - N.D. N.D. 
W796A 25.24 24.13 1.6  -  -  -  -  -  -  ++ Tiny 
 
Mutants that were not used for specific assay are indicated hyphen (-). IFA and plaque assay 
results are categorised into: strong (++++), weak (++), non-determined (N.D.). 
 




may possibly revive genomic RNA replication. Additional studies 
should as well be done to examine the biological relevance of K402, 
F486, G605 and Y607 replication fitness in the context of the DENV 2 





 DENV NS5 RdRp is an attractive target for antiviral development. 
This study represents the first observation in characterising the 
mechanism of action of residues F399, K402, F486, N493, G605, Y607, 
N610, D664 and W796 in the RdRp domain inhibitor binding pockets. 
Of all the nine DENV NS5 RdRp amino acid residues tested, our 
results have shown that residues F399, K402, N493, Y607, N610 and 
D664 are essential for DENV genomic RNA replication. Thus, these 
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